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ADH       Attention Deficit/ Hyperactivity 
CBCL     Child Behaviour Checklist 
DAT       Dopamine Transporter 
DEA       Drug Enforcement Agency 
GMDS    Griffiths Mental Developmental Scales 
GQ         General Quotient 
HIV        Human Immunodeficiency Virus 
IUGR     Intra-uterine growth restriction 
MA        Methamphetamine 
MRI       Magnetic Resonance Imaging 
MRS      Magnetic Resonance Spectroscopy 
NICU     Neonatal Intensive Care Unit 
PET       Positron Emission Tomography 
SGA      Small for gestational age 
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Methamphetamine, part of the amphetamine group of drugs, was first discovered in 
Japan in 1919. It has been clandestinely manufactured in the United States since the 
1960s, and is still legally produced there as a nasal inhalant, as treatment for 
Attention Deficit Disorder and exogenous obesity, as well as off-label treatment for 
narcolepsy. (1) 
It is a cheap (about R15-30 per ‘straw’), easily obtainable, odourless, white powder 
which has a bitter taste, but dissolves easily in water or alcohol. Known as, amongst 
others, ‘ speed’, ‘ice’, ‘crystal’, ‘chalk’, ‘glass’, ‘crank’, and locally, ‘tik’, it can be 
smoked, snorted, orally ingested, injected intravenously or even administered anally. 
In South Africa the preferred method consists of placing the powder or crystal in a 
light bulb (from which the metal threading has been removed) and inhaling the fumes 
produced while heating the bulb from below with a lighter.(2) 
 
The use of methamphetamine has risen sharply globally over the last decade, used 
by 26 million people worldwide by 2007, more than heroin and cocaine combined, 
according to the United Nations Office on Drugs and Crime. This has been ascribed 
to many interlocking reasons: it is cheap, easily obtainable, easy to use without the 
need for needles or other spec al ‘equipment’, and it produces in the user a 
characteristic ‘rush’. This feeling of confidence, power and heightened sexual levels, 
of feeling ‘on top of the world’ has made it especially popular amongst teenagers and 
young adults. (3)  
 
According to an article in the Wall Street Journal of May 21 2007, South Africa has 
become attractive both as a market and trade hub for recreational drugs, especially 
methamphetamine (4). Reasons cited include the fact that incomes are higher than 
most of the rest of Africa, banking and transport systems resemble that of a 
developed nation, with direct flights to any destination in the world as well as efficient 
seaports and reliable telephone and internet service. These factors, combined with 
an overwhelmed justice system has led to the perception of South Africa being a 













According to figures obtained via the Medical Research Council’s South African 
Community Epidemiology Network on Drug Use there has been a sharp rise in 
patients presenting with Methamphetamine-related problems since 2002. (2) 
Table 1 shows the proportions of patients presenting with methamphetamine as 
primary or secondary substance of abuse since January 2002 (this period has been 
divided into six month periods where 2002a refers to January – June 2002 and 
2002b to July – December 2002 and so forth). The figures quoted under ‘total 
patients’ refer to the total number of patients treated at over 25 specialist treatment 
centres or programmes for all substances (including methamphetamine, Mandrax, 
heroin, cocaine, alcohol, cannabis etc). 
Figure 1 provides a graphic illustration of these numbers. (Illustrations used courtesy 














Figure 2 shows the distribution of ages of patients who reported Methamphetamine 
as their primary substance of abuse- in the second half of 2007 the average age was 
23 years and 73% of these were male. Most were coloured (87%), 10% were white, 





















Besides the initial feeling of euphoria, increased confidence and heightened libido 
experienced after taking methamphetamines, these drugs have a number of adverse 
effects. They trigger release of neurotransmitters epinephrine, norepinephrine and 
dopamine in the sympathetic nervous system. (2) Release of these substances 
cause euphoria, increased energy and self-confidence, insomnia, restlessness, 
irritability and tremors, and heightened libido. Other systems outside the central 
nervous system are also affected. Respiratory effects include tachypnoea, 
pulmonary hypertension and pulmonary oedema as well as decreased lung capacity, 
while its effect on the cardiovascular system include tachycardia, hypertension 
and/or arrhythmias. Overdose can lead t  dehydration, hyperthermia, seizures, renal 
failure, stroke and myocardial infarction. Long-term use of tik leads to severe weight 
loss due to decreased appetite, severe dermatological problems, increased risk of 
seizures as well as uncontrollable rage, violent behaviour and personality changes. 
 
Women referred to the Alcohol Drug and Pregnancy Team (ADAPT) at National 
Women’s Hospital in New Zealand showed high rates of psychological, social and 
health problems related to their drug use. (5)  
















Figure 3: Psychosocial and health factors in patients 
Psychosocial and Health factors   N= 34 
Multiple drug use, incl cigarettes (33), marijuana (14), alcohol (10), 
opiates (6) 
 33 
History of not keeping appointments for antenatal check-ups  14 
Mental health problems, incl psychotic behaviour and attempted 
suicide 
 10 
Referrals to Child, Young Persons and Family Service  10 
Custody issues due to unstable home environment  7 
Legal proceedings pending for mother or imprisonment  5 
Medical complications prenatally  4 
Known history of overdose 2
Thus far, much of what is known about methamphetamine use in pregnancy and its
effect on the fetus, newborn and child has come from animal studies, human studies
(with varying methodologies) and information and literature on cocaine use in
pregnancy. All illicit drugs are known to cross the placenta and therefore reach the
growing fetus (6,7), causing direct effects on the fetus, or secondary to changes in
the fetal environment. Methamphetamine has been shown to have vasoconstrictive
effects leading to decreased uteroplacental perfusion, with subsequent restriction of 
nutrition and oxygen supply to the fetus and fetal hypoxia, and its anorexic effects on
the mother may result in intrauterine growth retardation. The drug can also permeate
the placenta itself and lead to prenatal stroke and other organ damage. Increased
maternal blood pressure and heart rate substantially raises the likelihood of 
miscarriage and premature delivery (8). Associated unstable home circumstances,
use of other drugs and potential dangerous sexual behaviour add to the risk of 
immediate complications and long-term sequelae in the unborn child.
Animal studies done on rats and their offspring have found a number of physical, 
motor, neurotransmitter and behavioural effects after exposure to methamphetamine 












structural defects such as retinal defects (9-11), cleft palate and rib malformations. 
Decreased growth and delayed motor development (10, 12) have also been 
demonstrated, as well as neurochemical alterations in the central nervous system 
secondary to neurotoxic effects of methamphetamine on serotoninergic neurons (9, 
12, 14, 15).These neurochemical alterations seem to be associated with learning 
impairment (9), increased motor activity (10), behavioural disturbances (14) and 
enhanced conditioned avoidance responses (12).  
 
The few human studies reported to date have shown similar patterns to those done 
in animals. Methamphetamine use seems to be associated with increased risk of 
premature delivery and placental abruption (16, 17), as well as clefting, cardiac 
anomalies and fetal growth retardation (18). One study, which used MRI to assess 
global brain volumes and regional brain structures, showed a definite correlation 
between methamphetamine use in pregnancy and smaller subcortical volumes and 
cognitive deficits in children exposed to prenatal methamphetamine (19).  
 
Maturation of the brain and central nervous system requires a sequence of events 
and processes more complex than that of any other system or organ, making it 
especially vulnerable to prenatal environmental influences (20, 21). The blood-brain 
barrier of the fetus and young infant is much more permeable than that of the older 
child and adult, and the fetus lacks efficient drug-metabolising detoxification 
capacities (22). Toxins associated with in utero growth retardation and maturational 
delay should be suspected of causing functional developmental toxicity. Therefore 
any substance or compound that causes retardation of intrauterine somatic growth 
should be considered a potential neurobehavioural teratogen (23). 
Methamphetamine complies with all these characteristics, and therefore warrants 
closer evaluation.  
 
Identification of specific neurodevelopmental and neurobehavioural deficits in 
children prenatally exposed to methamphetamine would enable a primary health 











potential problems and provide early, prophylactic care to the exposed child, thereby 
limiting long-term developmental and cognitive sequelae. Large areas of South 
Africa remain underserved by medical and social services, and lower socio-
economic status leave these children especially vulnerable. 
SCREENING FOR DEVELOPMENTAL DELAY AND LEARNING DISABILITIES 
The most reliable measure of neurodevelopment remains serial neuropsychological 
testing, but developmental delay and other specific disabilities can be identified using 
specific neurological and developmental observations and assessments as well as 
parental reports.  
The optimal selection of tools for any such research would be those that tap into the
specific areas known to be affected by the compound under investigation. However, 
this assumes that information already exists on the effect of that substance on the
developing nervous system. Where such information is non-existent or scanty, it is 
necessary to use a wider spectrum of assessment tools. 
Complete evaluation of any child with a potential neurodevelopmental delay or 
learning disability should commence with a thorough physical examination,
especially searching for other, identifiable syndromes associated with these delays, 
as well as a thorough neurological exam, vision and hearing assessment, head
circumference and growth parameters . Developmental examination should ideally
be performed with the help of a formal battery of psychoeducational tests
administered by an appropriately trained individual and should focus on processing,
recall, integration and output of auditory and visual information. 
Such comprehensive testing includes (70): 
 A reliable, stable and valid measure of intellectual ability
 Measures of aural, motor and visual processing
 Measures of vocabulary and language development
 Measures of academic achievement
 Measures of attention regulation












AIM OF THIS STUDY 
 
To determine whether specific neurodevelopmental or neurobehavioural deficits can 
be identified in a cohort of South African children known to be antenatally exposed to 










Children to be included in the study will be those born at New Somerset Hospital, 
Groote Schuur Hospital and Mowbray Maternity Hospital during the period January 
2004 to June 2007, whose mothers had disclosed at the time of delivery that they 
had been taking methamphetamine during their pregnancy. Occasionally this 
information had been noted in the Neonatal Intensive Care Unit (NICU) admission 
book, but referrals by the NICU or obstetric service to a social worker for 
methamphetamine use during pregnancy will also be used as a source of 
recruitment. History of other drug or alcohol use or cigarette smoking during 
pregnancy will be obtained from reviewing NICU charts as well as parental interview 
at the time of testing.    Parental consent will be taken before inclusion into the study.  
 
Approximately 15 such children are known at present through disclosure of mothers 
at the time of delivery and the noting thereof in the newborn’s folder at the New 
Somerset Hospital. Unfortunately, to date, no official database exists in South Africa 
of methamphetamine-exposed children to ease identification of these children for a 
study such as this. 
 
Children will be excluded from the study if there is other pathology that would impact 












meningitis, or pre- or postnatal insults such as hypoxic ischaemic encephalopathy or 
severe neonatal hypoglycaemia or another syndrome with known developmental 
delay; or if parental consent is denied. Infants of all gestations will be included, as 
premature delivery is a known complication of methamphetamine use in pregnancy. 
All folders will be reviewed carefully as part of the study, to add information and to 
carefully screen for other pathology. A detailed medical history will also be taken at 
commencement of the study - of the child, family and mother before and during 
pregnancy.  We will also indicate in our findings whether any of our index cases have 
been or are currently in foster or other protected care. 
 
A control group of children matched to the previous group for age, sex, and as far as 
possible, background, birth circumstance, gestation and schooling, will also be 
evaluated. These children will be identified from records of babies born at New 
Somerset Hospital, Groote Schuur Hospital and Mowbray Maternity Hospital within 
six months age of index cases with all attempts made to minimise vast differences in 
background, schooling and socioeconomic status, since the hospital has quite 
specific drainage areas. Attempts will be made to match index cases to controls 1:2, 
to increase the power of any positive findings. Controls will be included pending 
parental consent and the same exclusion criteria as the first group. 
In an attempt to boost numbers and increase the power of any findings, data from 
control cases from another study (investigating the neurodevelopmental outcomes of 
children whose mothers were HIV positive) will also be added. These controls had 
been selected from exactly the same geographical area, had the same exclusion 
criteria, ages, socioeconomic background and educational possibilities as our control 
group. Ethics approval had been obtained for the other study and permission 
obtained from the study executive to use the data. 

















Consent will be obtained from the parents of all test and control subjects before 
inclusion into the study. It will take the form of a verbal explanation by one of the 
investigators (with the help of an interpreter where necessary to make information 
accessible to the parent in their first language) as well as written material provided to 
both families of patients (Appendix A) and controls (Appendix B). The consent form 
to be signed by the parent will also be available in the family’s first language (All 
current potential subjects have either Afrikaans or English as first language, but the 
consent form and all information will be translated into other languages such as 
Xhosa, should the need arise.) 
 
Where possible and appropriate, verbal assent will be sought from children 
themselves.  
Information will be treated as strictly confidential and family’s privacy protected as far 
as possible. 
This study protocol will also be submitted to the Red Cross Children’s Hospital 





At present all expenses incurred in the completion of this study will be carried by the 
principal investigator. There are currently no outside sponsors and therefore no 
possible conflict of interests. An application will be submitted to the School of Child 
and Adolescent Health Research Fund for assistance in covering expenses incurred 














Measures of testing 
 
A battery of tests will be performed on both children known to have been exposed to 
methamphetamine in pregnancy, as well as the control group. Every attempt will be 
made to keep testing times as short as possible, especially for smaller children, and 
to provide resting time and snacks in between to prevent fatigue from influencing test 
results.  
Full confidentiality will be observed with respect to results of testing as well as 
personal information received from families, especially considering the sensitive 
nature of the exposure. This will also be clearly indicated in the consent form. 
 
Screens to be used: 
1. Griffiths Mental Developmental Scales (appropriate for ages 3-7 years) (57, 
58, 59, 60, 61) 
2. The Achenbach Parent Questionnaire (67) 
 
 
The Griffiths Mental Development Scales will be performed on all subjects. All 
parents and guardians will be asked to complete the Achenbach Parent 
Questionnaire. 
 
Parents or legal guardians will also be requested to complete a short questionnaire 
regarding amongst other factors income, housing, marital status, highest level of 
education of the mother (or main caregiver in the event of an absent mother) to 
assist in comparing background and socio-economic factors that may affect 
development. 
 
Testing will be performed at the Red Cross Children’s Hospital’s Developmental 












Testing will where possible be performed only by Dr Jessie van Dyk, under 
supervision and with assistance by Dr Kirsten Donald. Families will be provided with 
monetary remuneration for transport costs, meals and snacks for the day of testing. 
 
Note: study protocol amended to remove neurodevelopmental assessments 
previously planned (Test of Reception of Grammar, Beery Buktenika Test of Visual 
Motor Integration and Goodenough Draw-A-Man Test had previously been included 
in study protocol but made the assessment too long for children of 2-4 years to 
complete successfully) 
 
Predicted project duration  
 
Commencement of testing (pending ethical and research committee approval): 
February 2009 




Initial patient data and testing results will be written onto case report forms, where 
after it will be entered into a computer database and analysed with the help of 
standard statistical methods. The process of final analysis will be done under the 
supervision of a qualified medical statistician, to ensure that all conclusions drawn 




Upon completion of testing the parent or primary caregiver will receive a copy of the 
report of neurodevelopmental and neurocognitive testing. Direct feedback to the 
child’s school or pre-school will also be done in cases where problems are identified 











as far as possible in finding assistance with other medical, behavioural, as well as 
social problems identified during this study. 
This applies to the control group as well as the groups of known exposed children.  
OUTCOMES 
Identifying possible specific developmental and neurobehavioural problem areas in
children exposed to methamphetamine during pregnancy will assist doctors and
other members of the multidisciplinary team involved in the care of the child to be
vigilant of these potential problems, provide early, more intensive developmental
care and educational support to these children, and thereby improve their final
educational outcome, their ability to function optimally and their quality of life. It
would also assist healthcare workers in counselling parents, other primary caregivers
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Methamphetamine use in pregnancy and subsequent 
neurodevelopmental sequelae in the child: a review of the literature 
The objective of this structured review of the available literature was to identify 
potential neurodevelopmental and psychological effects in children exposed to 
methamphetamine during pregnancy.  
 
Literature search strategy 
The following four databases were searched up to June 21, 2011: OVID MEDLINE 
from 1948, EMBASE from 1980, PsycINFO from 1967 and Cochrane Central 
Register of Controlled Trials from second quarter 2011.  The strategy used terms 
customized for the database derivations of the terms methamphetamine AND 
pregnancy AND neurocognitive or developmental outcomes.  Reference lists of all 
retrieved manuscripts were searched for all articles not previously identified. A total 
of 617 references were retrieved from all 4 databases.  All references were then 
saved in an EndNote library used to identify the 116 duplicates. The remaining 501 
unique references were then reviewed against my inclusion criteria. See Appendix J 
for exact search strategy outlines. 
 
Methods of the review 
Published literature identified by the above search as potentially relevant to the topic 
being investigated, were then retrieved and individually scrutinized. Due to the 
relative paucity of material on the topic under review, different types of publications 
had to be included. Other literature reviews, original research including retrospective 
cohort studies and even case studies were assessed in an attempt to identify the 
type and presentation of potential neurodevelopmental, behavioural and 
psychological effects that could be expected in children exposed to 
methamphetamine in pregnancy. In a further attempt to identify potential effects, 











exposed to antenatal methamphetamine use, as well as animal studies identifying 
potential structural and developmental effects of antenatal methamphetamine 














Methamphetamine belongs to the amphetamine family of drugs, and was first 
synthesized in 1893, 6 years after the first member of this group of compounds, 
amphetamine, in 1887 (1). Clandestinely manufactured in the United States since 
the 1960s, it is still legally produced there to treat Attention Deficit Disorder and as 
short- term treatment of exogenous obesity, as a nasal inhalant, and as off-label 
treatment for narcolepsy (2). It is classified by the Drug Enforcement Agency (DEA) 
as Schedule II (having acceptable medical uses but requiring tight control due to 
their potential abuse leading to significant psychological and physiological 
dependence). Amphetamines cause their psychostimulant effects and characteristic 
‘rush’ by increasing synaptic biogenic amine levels, including dopamine, 
norepinephrine and serotonin (1). This feeling of increased confidence, power and 
libido has made it especially popular among teenagers and young adults (3). When 
compared to cocaine, both drugs reverse monoamine transporter action and 
increase the release of dopamine, norepinephrine and serotonin in the synaptic cleft, 
as well as blocking the reuptake and breakdown of these neurotransmitters, further 
increasing their availability in the synaptic cleft. Methamphetamine, though, has an 
added methyl group, which makes it more readily absorbable though lipid-permeable 
membranes.  
Besides the initial euphoria brought on by the drug’s stimulant effects, there are also 
a vast array of short and long term adverse effects due to the increase in 
neurotransmitter release. These include insomnia, restlessness, irritability and 
tremors. Other systems outside the central nervous system are also frequently 
affected leading to respiratory effects (tachypnoea, pulmonary hypertension and 
pulmonary oedema as well as decreased lung capacity), cardiovascular effects 
(tachycardia, hypertension and/or arrhythmias), long-term complications such as 
severe weight loss due to decreased appetite, severe dermatological problems, 
increased seizure risk, as well as behavioural changes such as uncontrollable rage, 
violent and aggressive behaviour and personality changes. Both hemorrhagic 
strokes (including intracerebral and subarachnoid haemorrhages) and ischemic 












users also often suffer from nutritional deficiencies, are prone to serious traumatic 
injuries (5) and are more likely to be affected by infectious diseases such as sexually 
transmitted diseases and HIV (6). 
Signs of methamphetamine overdose include hyperthermia (historically referred to 
as ‘Saturday Night Fever’), rhabdomyolysis, cardiomyopathy, dehydration, renal 
failure, disseminated intravascular coagulation, seizures, stroke, psychosis and 
myocardial infarction (7). 
Methamphetamine (known locally in South Africa as, amongst others, ‘speed’, ‘ice’, 
‘crystal’, ‘chalk’, ‘glass’, ‘crank’, and especially ‘tik’), is cheap, easily obtainable, 
odourless and can be taken in by various methods (smoking, snorting, oral ingestion, 
intravenous injection and by placing the powder in a light bulb and i haling the fumes 
while it is heated from below) (8). 
Methamphetamine use has been increasing steadily over the last decade, the last 
estimate being 26 million people worldwide (more than the estimates for heroin and 
cocaine use combined) according to the United N tions Office on Drugs and Crime. 
In South Africa methamphetamine use has seen a steady marked increase over the 
last ten years. Pluddeman et al investigated the trends of treatment demands for 
substance abuse, with methamphetamine as primary or secondary drug of abuse, at 
treatment centres in the Western Cape province of South Africa, and found that the 
numbers had risen from less than 1% in 2002 to 51% by 2006 (9). A fact sheet 
published by the Medical Research Council of South Africa demonstrated the same 
trends with a steady rise still observed by 2008 (7). 
When analysing referrals to the Alcohol Drug and Pregnancy Team (ADAPT) at 
National Women’s Hospital in New Zealand, female clients showed high rates of 
psychological, social and health problems related to their drug use. (9) See Table 1 















Table 1: ADAPT referral trends for female clients at National Women’s Hospital, New 
Zealand 
1.0 Psychosocial and Health factors 2.0    N= 34 
Multiple drug use, incl cigarettes (33), marijuana (14), alcohol (10), 
opiates (6) 
   33 
History of not keeping appointments for antenatal check-ups    14 
Mental health problems, incl psychotic behaviour and attempted 
suicide 
   10 
Referrals to Child, Young Persons and Family Service    10 
Custody issues due to unstable home environment    7 
Legal proceedings pending for mother or imprisonment    5 
Medical complications prenatally    4 
Known history of overdose    2 
 
Current knowledge of the effects of antenatal methamphetamine exposure 
Thus far, much of what is known about methamphetamine use in pregnancy and 
how it affects the fetus, newborn and child has come from animal studies, a few 
human studies (with varying methodologies) and literature on cocaine use in 
pregnancy. All illicit drugs are known to cross the placenta and therefore reach the 
developing fetus (11, 12), affecting it either directly or secondary to changes in the 
fetal environment. Methamphetamine has been associated with placental abruption 
(8), and has also been shown to have vasoconstrictive effects leading to decreased 
uteroplacental perfusion, with subsequent restriction of nutrition and oxygen supply 
to the fetus and fetal hypoxia. Maternal effects such as hypertension and anorexia 
may potentially lead to miscarriage, premature delivery and intrauterine growth 
retardation. The drug can also permeate the placenta itself, leading to other 
complications such as prenatal stroke and other organ damage secondary to 
hypoxia and hypoperfusion. One cohort study looking at factors significantly 
associated with methamphetamine identified, amongst others, low Apgar scores (6% 
compared with 1-2% in controls), need for caesarean section (29% compared with 
23%), preterm delivery (52% compared with 17%) and neonatal mortality (4% 












using methamphetamine during pregnancy were more likely to be younger, have 
poorer general health, living without a partner, have a lower income, be less 
educated and be less likely to receive good prenatal care. Add to this the unstable 
home circumstances, risky sexual behaviour and potential use of other substances 
and immediate complications and long-term developmental sequelae in the 
developing fetus become logical outcomes. Apart from the apparent prenatal effects 
of methamphetamine use, breast milk amphetamine levels have also been shown to 
be up to seven times higher than that of maternal plasma levels (14). 
 
Findings from animal research 
Animal studies have identified a number of effects after exposure to 
methamphetamine (15-20), including increased maternal and child mortality, retinal 
defects, cleft lip and palate, rib malformations, poor growth and delayed motor 
development. One review also suggested lower birth weights, deficits in visual 
system development, an increased incidence of microgyri, impaired spatial learning, 
sensory-motor coordination and postural motor movements, and increased startle 
reflexes. An interesting observation of the same study was that the impaired 
sensory-motor coordination appeared to be transmitted to the next generation of off-
spring as well, even without subsequent methamphetamine exposure (21). 
Research done in monkeys found hyperaemia, hemorrhage and glial proliferation 
after exposure to high doses of amphetamines, while in cats the same exposure lead 
to enlarged chromatolytic medullary neurons (1). Rodents exposed to parenteral 
doses of amphetamines showed reduced dopaminergic terminals, decreased 
serotonin levels and swollen or reduced dopaminergic terminals. The mechanism 
behind amphetamine-induced neurotoxicity remains somewhat unclear, but the 
theory seems to be that the high levels of cytoplasmic dopamine produced by the 
disruption of vesicular storage eventually produces accumulation of reactive oxygen 














Data from human research literature 
The few available human studies have identified similar patterns, demonstrating an 
increased risk of premature delivery and placental abruption (24, 25), cleft lip and 
palate, cardiac anomalies and intrauterine growth restriction (26). The Infant 
Development, Environment and Lifestyle Study (IDEAL) showed that 
methamphetamine/ cocaine-exposed neonates consistently had lower birth weights 
and smaller head circumferences than non-exposed neonates and were more likely 
to be small for gestational age (SGA) as calculated by Alexander’s algorithm (27). 
Actual immediate withdrawal symptoms due to exposure to these stimulants are 
usually less severe than that of opiate withdrawal in the neonatal period, but one 
study described that up to 49 percent of neonates exposed to methamphetamine 
antenatally exhibited signs such as abnormal sleep patterns, tremors, hypertonia and 
poor feeding, although only 4 percent of exposed neonates required medication for 
withdrawal (8). A review published by Thompson et al linked methamphetamine and 
amphetamine exposure during fetal development with low birth weight, decreased 
arousal during the neonatal period, increased stress responses, and later: movement 
disturbances and decreased scholastic achievement (21). These same children 
demonstrated poorer performance on sustained-attention, long-term spatial and 
verbal memory, and visual motor-integration tests, although the wide age range in 
this last study (3-16 years) make the findings harder to interpret.  
 
Brain and central nervous system development and maturation requires a carefully 
patterned sequence of events and processes more complex than that of any other 
system or organ, making it particularly vulnerable to prenatal environmental 
influences (28, 29). The blood-brain barrier of the developing fetus is much more 
permeable than that of the older child and adult, and the fetus lacks efficient drug-
metabolising detoxification capacities (30). Also, there should always be concern 
regarding any toxin associated with in utero growth retardation and delay of 
maturation causing functional developmental toxicity, and therefore these toxins 
should be considered potential neurobehavioural teratogens (31). Methamphetamine 











of the growing fetus and its milieu as evidenced above, and therefore merits closer 
evaluation. 
Neurodevelopmental findings on assessment of methamphetamine-exposed 
children 
Few studies have looked at long-term neurocognitive effects of antenatal
methamphetamine exposure. Of the small number of publications available, even
fewer have examined the pre-school population. Prospective studies following
methamphetamine-exposed children up to 15 years of age had found an increase in
aggressive behaviour (32) and delays in language, performance in physical fitness 
activities and mathematics (33). These studies had several limitations, especially the
earlier study, including concomitant antenatal alcohol and cigarette exposure, as well
as the absence of a control group. Socio-economic status and its effect on the
findings in these studies were also never investigated.
Another group or researchers followed children exposed to amphetamine during
pregnancy and reported the following: by age 1 these children were exhibiting
emotional characteristics of autism, speech difficulties and stranger wariness (34); by 
age 4, when compared with the norm for Swedish children, their IQ’s were lower
(32); by age 8 they exhibited more aggressive behaviour and problems with peers
(35) and by age 14 they showed significant problems with school advancement
(especially due to delays in mathematics and language) and physical fitness 
activities (33).
Abnormal neuro-imaging findings thought to be associated with antenatal 
methamphetamine exposure 
Older studies looking at cranial ultrasound in children with prenatal 
methamphetamine and cocaine exposure showed an increased incidence of 
intraventricular hemorrhage and white matter densities (36). Neuroimaging studies 
have demonstrated abnormalities in brain structure and chemistry (37). In children 












showed smaller striatal structures, while Magnetic Resonance Spectroscopy (MRS) 
demonstrated elevated total creatine levels, possibly a reflection of mitochondrial or 
glial cell dysfunction. Positron Emission Tomography (PET) in adult 
methamphetamine users have also shown reduced dopamine transporter (DAT) 
density and decreased dopamine D2 receptors in the striatum. Similar studies 
investigating the effect of repeated exposure to methamphetamine in rodents proved 
toxic effects on dopaminergic and serotonergic neurons (38, 39). Since chronic 
dopamine D2 receptor blockade could potentially lead to increased striatal trophic 
activity during fetal development, a decreased basal ganglia volume found in 
children with antenatal methamphetamine-exposure suggests deficient dopamine 
function (40). 
One study compared global brain volumes and regional brain structures on MRI, as 
well as performance in neurocognitive assessment of children exposed to 
methamphetamine antenatally with unexposed controls (41). MRI showed 
comparable whole brain volumes in both groups, but smaller putamen bilaterally (-
17.7%), smaller globus pallidus (left -27%, right -30%), smaller hippocampus 
volumes (left -19%, right -20%) and a trend towards smaller caudate bilaterally (-
13%) in children with antenatal methamphetamine exposure. No difference was seen 
in volumes for the thalamus, midbrain or cerebellum. The changes seen on MRI 
correlated with lower scores on measure of visual motor integration, attention, verbal 
memory and long-term spatial memory in the methamphetamine-exposed group. 
Another study found evidence that damage to the fronto-striatal circuit in children 
exposed antenatally to methamphetamine, was associated with suppression of 
activation in those brain regions involved in performing working memory tasks (42).  
One study examining children aged 7-15years by functional MRI while performing a 
verbal paired associate learning task showed that methamphetamine-exposed 
children activated more diffuse brain regions, including regions in the medial 
temporal area bilaterally, known to be essential to memory, when compared to 
children exposed to only alcohol prenatally and children with no known drug 
exposure in pregnancy (43). These findings suggest an attempt to recruit 
compensatory systems to support a weaker verbal memory network. Other possible 
extrapolations are that children with antenatal methamphetamine exposure activate 











Chang et al compared MRS and neurocognitive testing in methamphetamine-
exposed children matched with non-exposed children (44). The methamphetamine-
exposed group were found to have higher total creatine, N-acetyl compounds, total 
creatine and glutamate+glutamine concentrations in the frontal white matter 
(suggesting higher neuronal density or cellular compactness in the white matter), but 
lower myoinositol and myoinositol/total creatine concentrations in the thalamus 
(suggesting a lower glial content and corresponding with poorer performance on a 
visual motor integration task), even when matched for head circumference, parental 
education, intelligence, global cognitive function and socio-economic status.  
Alterations in white matter maturation have also been suggested in children exposed
to methamphetamine during fetal life, as demonstrated by lower diffusion on diffusion
tensor imaging (DTI) (45). This finding was thought to reflect more compact axon
density or higher dendritic or spine density.
Expansion of studies such as these to exactly delineate the full spectrum of 
neurocognitive effects and how they manifest in the learning environment would be
valuable in providing educational and social support to this growing population.
The effects of methamphetamine exposure on adult users are well documented and
overwhelming evidence shows that methamphetamine exposure during pregnancy
has significant effects on the pregnant mother and subsequently on the growing
fetus’ developmental milieu antenatally, as well as it’s environment and therefore
development post-natally. Although not fully characterised, particular structural
defects of the brain a d central nervous system, amongst others, have been shown
in animal literature and suggested in human subjects (15-21, 24-27). By reviewing
the available literature specific areas of developmental and behavioural concern
have been identified, including aggressive behaviour (29), delays in language,
performance in physical fitness activities and mathematics, emotional characteristics 
of autism, speech difficulties and stranger wariness (34); and significant problems
with school advancement (again especially due to delays in mathematics and
language) (33). Exposed children demonstrated lower scores on measures of visual
motor integration, attention, verbal memory and long-term spatial memory.
Increased complication rates, number of admissions to neonatal intensive care units 











costs to all government support systems. In the era of preventative health care 
knowing which problems to anticipate would benefit society as well as the child and 
its family. Identifying specific neurodevelopmental and neurobehavioural deficits in 
children exposed to methamphetamine prenatally would enable the child’s primary 
health care provider as well as the interprofessional team at all levels to be vigilant of 
potential problems and provide early, directed care to the exposed child, thereby 
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Aim: To identify neurodevelopmental or behavioural deficits among children exposed to 
maternal methamphetamine (MA) use during pregnancy. 
Methods: Griffiths Mental Developmental Scales assessments were completed on 15 
toddlers aged 2-4 years with a known history of maternal methamphetamine use during 
pregnancy. These were compared to 21 controls without a history of maternal 
methamphetamine use. Each child also had a hearing test, vision screen and Child 
Behaviour Checklist completed by a parent or caregiver. Cases and controls were matched 
for age, gestational age at birth, socio-economic status and geographic distribution.  
Results: Fifteen toddlers were assessed and compared to twenty-one controls Baseline 
comparison revealed no significant difference between age at testing, gestational age, socio-
economic status or geographic distribution. Methamphetamine-exposed children obtained 
lower scores on General Quotients (p=0.0220), but significantly poorer performance was 
noted specifically on the Personal-Social Ability Subscale (p<0.0001) and on the Hand and 
Eye Co-ordination Subscale (p=0.0002). There were also concerns regarding aggressive 
behaviour and attention deficit/hyperactivity on the CBCL for the exposed group, although 
this did not reach statistical significance. 
Conclusion: Among children exposed to maternal methamphetamine use during pregnancy, 














Methamphetamine (MA) use has risen sharply in South Africa over the last decade 
(1), with increasing numbers of newborns delivered daily with known maternal 
methamphetamine use during pregnancy. In Cape Town and surrounds, admission 
trends to substance abuse treatment centres, with methamphetamine as primary or 
secondary drug of abuse, had risen from less than 1% in 2002 to 51% by 2006 (1) 
and continues to rise. The effects of prenatal methamphetamine use on maternal 
and fetal well-being have been well documented, including maternal anorexia and 
hypertension, placental abruption and poor function and intra-uterine growth 
retardation. Preterm delivery and neonatal mortality rates are increased and Apgar 
scores frequently lower (2, 3, 4). Its effects on the developing brain, however, are 
less well defined. Animal literature has raised concerns of certain structural defects 
such as retinal defects, cleft lip and palate, rib malformations, poor growth and 
delayed motor development. Reviews have also suggested deficits in visual system 
development, an increased incidence of microgyri, impaired spatial learning, 
sensory-motor coordination and postural motor movements (up to a second 
generation), and increased startle reflexes (5-10). Human studies, with varying 
methodologies, have begun to postulate certain neuroradiological and 
neurodevelopmental sequelae that could be expected with prenatal maternal 
methamphetamine exposure (11-19). Magnetic Resonance Imaging (MRI) has 
shown a decrease in size of certain brain structures, while Magnetic Resonance 
Spectroscopy (MRS) has identified a difference in brain metabolite levels between 
methamphetamine-exposed and non-exposed children (19). Language delays (20), a 
delay in mathematics skills (21), autistic characteristics and other speech difficulties 
(22), as well as increased aggressive behaviour (23) have been among the specific 


















This is a descriptive case control pilot study 
SUBJECTS 
Children included in the study were those born at New Somerset, Groote Schuur and
Mowbray Maternity Hospitals in Cape Town, South Africa over a 2 and a half year
period (2004-2007) whose mothers had disclosed methamphetamine use during
pregnancy. This information was found either in neonatal intensive care unit (NICU)
admission logs or by records of referrals to a social worker. History of other drug use
or cigarette smoking during pregnancy was obtained through reviewing NICU charts 
as well as parental interview at the time of testing. Parental consent was taken
before inclusion into the study. 
Of the 52 eligible children only 15 could be found and recruited into the study. 
Reasons for exclusion included:
1) Refusal (2 children)
2) Untraceable families (34 children)
3) History of other pathology that might impact on their neurocognitive functioning
(serious head injury, bacterial meningitis, or pre- or postnatal insults such as hypoxic
ischaemic encephalopathy or severe neonatal hypoglycaemia or another syndrome
with known developmental delay) (1 child with head injury).
 Infants born at all gestational ages were included, as premature delivery is a known 
complication of methamphetamine use in pregnancy. Available hospital charts were 
reviewed carefully by the principal investigator, to add information and screen for 
other pathology. A detailed medical history was also taken at the first interview - of 
the child, family and mother before and during pregnancy.  We also indicated 













A control group of children, matched for age, sex, background, socioeconomic 
background, birth circumstance and gestation to the MA group were also evaluated. 
These children were identified from records of babies born at the same institutions 
and of within six months of the age of index cases in an attempt to minimise 
differences. Data from control cases from another study were also added to increase 
the power of any findings. These controls were drawn from the same geographical 
area, had the same exclusion criteria, ages and socioeconomic background. Ethics 
approval was obtained to incorporate data from these controls into our own study. 
Inclusion of control cases were subject to parental consent and the same exclusion 
criteria.  
Maternal alcohol use during pregnancy amongst the mothers was also documented. 
Alcohol use during pregnancy as reported by mothers in the exposed and control 
groups was present in approximately equal numbers (see Table 1). 
 
ETHICAL CONSIDERATIONS AND CONSENT 
Consent was obtained from the parents or primary caregivers of all subjects before 
inclusion. Where literacy was questionable, information was read to parents or 
caregivers and explained by one of the investigators. As all the parents, caregivers 
and children were either English or Afrikaans first language speakers, an interpreter 
was not required.  Written material was also provided to families. 
 
Information was treated confidentially and family’s privacy protected as far as 
possible. Where families requested further assistance by a social worker or other 
supportive services, their consent was obtained to share relevant information with 
these services. Where problems were identified during our assessments, parents 
and caregivers were offered the option of re-testing and follow-up in the 













The study protocol was approved by the University of Cape Town Human Research 




This included a questionnaire completed by parents or primary caregivers on social 
circumstances (family income), medical history, educational history (highest level of 
schooling obtained by parents of caregivers), current occupation, marital status. A 
detailed birth and perinatal history was also obtained. It was noted whether the child 
was in the care of his/ her parents, other family members or other protective care. 
 
Cognitive and Behavioural tools 
Developmental testing was performed on each child in the methamphetamine-
exposed as well as the control group. The Griffiths Mental Developmental Scales 
(GMDS) was administered by the principal investigator or co-supervisor, Dr Kirsten 
Donald.  
The GMDS assesses comprehensively the different aspects of normal infant and 
child development. It has been validated (but not yet standardised) for use in 
children of different language groups (English, Afrikaans and Xhosa) in South Africa 
(24). The GMDS measures areas, or ‘sub-scales’ of development under the 
categories Locomotor Subscale, Personal-Social Subscale, Hearing and Speech, 
Eye and Hand Co-ordination Subscale, Performance Subscale and Practical 
Reasoning. 
 
Raw scores from all the separate sub-scales are added to obtain a total raw score 
that can be converted and evaluated as either age equivalents, sub-quotients and 
general quotients (the GQ or general intellectual ability), or percentile equivalents. 













The GMDS was administered in each child’s home language (Afrikaans or English). 
No external translator was required. 
 
The Child Behaviour Checklist (CBCL) (30, 31) is completed by parents or guardians 
and is designed to assess behavioural problems and social competencies in 
children. It has been extensively validated across widely differing socioeconomic and 
cultural spectrums (32).  
In addition to arranging the results of scores in 7 syndrome categories (eg 
Emotionally Reactive, Anxious/ Depressed), it provides 3 more general scores: a 
total score, a score on internalising behaviours (anxious and inhibited) and 
externalising behaviours (aggressive and under-controlled). The questionnaire also 
classifies behavioural scores according to more familiar Diagnostic Statistic Manual-
IV (DSM-IV) related categories (Affective Problems, Anxiety Problems, Attention 
Deficit/ Hyperactivity Problems). The recommended t-score transformation of the raw 
behaviour scores was used. A t-score of >63 in the general scores or t-score of >69 
on the individual syndrome subscales represents clinically meaningful symptoms 
(32). In this study we used the 18 month to 5 year age version. 
 
Testing occurred in the Developmental Paediatrics Outpatient Clinic consulting 






















The scores in our dataset were linearly transformed from the original raw data to 
obtain z-scores, percentiles and age-equivalents in the case of the Griffiths Mental 
Developmental Scales and t-scores and percentiles in the case of the Child 
Behaviour Checklist. Raw data was used to do the statistical analysis, though, and 
as the groups were matched at the onset of the study, only univariate analysis (t-
test) was performed. (For the purpose of where an individual falls in the distribution 
of the general population, z-score is useful, whereas raw data is more appropriate 
when comparing two groups.) 
No adjustments were done for multiple tests. Minimum and maximum scores, 
means, medians, upper and lower quartiles were obtained for data in the GMDS and 
CBCL, and p-values derived to delineate statistical significance of any differences in 









































Ethnic Background   
African n=0 n=0 
Mixed n=15 n=21 
European n=0 n=0 
Parental education   
Mother   
<Gr 7 n=2 n=0 
Gr 8-11 n=10 n=1 
Gr 12 n=2 n=2 
>Gr 12 n=0 n=0 
Unknown n=1 n=18 
Father   
<Gr 7 n=3 n=0 
Gr 8-11 n=1 n=1 
Gr 12 n=1 n=1 
>Gr 12 n=0 n=0 
Unknown n=10 n=19 
Guardian    
<Gr 7 n=6 n=0 
Gr 8-10 n=4 n=0 
Gr 12 n=0 n=0 
>Gr 12 n=0 n=0 
Unknown n=1 n=0 
Parent/foster care   
Parent(s) n=4 n=21 
Foster (all grandmother) n=11 n=0 
Alcohol use in 
pregnancy   
 n=3 n=2 
Gender   
Male n=9 n=14 
Female n=6 n=7 
Gestational age   
Term n=11 n=18 











(28, 30, 35, 
36 wks) 
(34, 34, 35 wks) 
Mode of delivery 
NVD n=8 n=15 
C/section n=4 n=2 
Unknown n=3 n=4 
Home language 
Afrikaans n=10 n=21 
English n=1 n=0 
Afrikaans/English n=4 n=0 
There was no known intra- or extra-uterine growth retardation in either group. 
All 15 methamphetamine-exposed children and 21 non-exposed controls had a 
completed GMDS and CBCL.  
NEURODEVELOPMENTAL ASSESSMENT 
Figure 1: Box plot characterising results for GMDS assessment in methamphetamine-
exposed children vs controls (using raw scores) 
In above table: A = Locomotor ability 
    B = Personal-Social Ability 
    C = Language (Hearing and Speech) 
    D = Eye and Hand Co-ordination 
    E = Performance ability 
    F = Practical Reasoning ability 





































































































Figure 2: Box plot characterising results for CBCL assessment in methamphetamine-
exposed children vs controls 
 
Legend: ER – Emotionally Reactive, AD – Anxious / Depressed, SC – Somatic complaints, W –
Withdrawn, Slp – Sleep problems, Att – Attention problems, Agg – Aggressive behaviour, Int – 
Internalising problems, Ext – Externalising problems, Tot – Total problems, Aff – Affective problems, 
Anx – Anxiety problems, PD – Pervasive Developmental problems, ADH – Attention Deficit/ 
Hyperactivity problems, OD – Oppositional Defiant problems 
 
Differences between the groups on general performance was statistically significant, 
where Mean age equivalent for methamphetamine-exposed children (MMETH)= 30.3;  
Mean age equivalent for control group (MCONT)= 36.8; p = 0.0220.  
There were also statistically significant differences between groups on some of the 
individual subscales, including performances in the Personal & Social subscale, 
where MMETH = 33.4; MCONT = 48.4; p <0.0001 and in the Eye and Hand Coordination 
subscale, where MMETH =26.5; MCONT = 33.6; p = 0.0002.  
Differences between groups in the following subscales approached statistical 
significance: in the Hearing & Speech subscale where MMETH =28.4; MCONT = 33.6; p 
= 0.0804; in the Performance subscale where MMETH =28.5; MCONT = 34.4; p = 











































































































































































Table 2: GMDS results for exposed and control groups (raw scores) 







control A 20 37.4 9.8 24 29.7 36.4 45 58 
 (N=21) B 21 48.4 8.9 32.4 44 48 54 64 
  C 21 33.5 8.2 18.8 28 34 36 50 
  D 21 33.6 5.1 24.1 30.7 32 36 44 
  E 21 34.4 8.3 18.9 29.4 32 40 52 
  F 21 32.9 8.0 21.8 27.3 29.9 36 50 
  G_tot 21 36.8 7.1 25.8 30.75 36.2 42.7 49.7 
Subject A 15 34.0 14.9 18.3 22.7 28 44 68 
 (N=15) B 15 33.4 10.7 19.3 23.5 31.5 42 54 
  C 15 28.4 8.5 18.9 21.1 26 38 44 
  D 15 26.5 5.2 20.8 21.5 24 30 34 
  E 15 28.5 10.2 14.5 22.1 25.4 38 46 
  F 15 31.1 8.9 24 24 26 42 50 
  G_tot 15 30.3 9.2 19.1 22.9 26.4 40.3 47 
          Score A B C D E F G_total 





0.5973 0.0002 0.1503 0.0005 0.0691 0.7331 0.0421 
 
In above table: A = Locomotor ability 
                         B = Personal-Social Ability 
                         C = Language (Hearing and Speech) 
                         D = Eye and Hand Co-ordination 
                         E = Performance ability 
                         F = Practical Reasoning ability 













Even when correcting for the two preterm infants in the methamphetamine-exposed 
group, the resulting p-values remain statistically significant in the same subscales 
(see table 2) 
 
BEHAVIOUR 
The cut-off for clinical relevance when categorising the behavioural scores for the 
different categories, is a t-score of ≥70. A t-score of between 65 and 69 is borderline.  
Methamphetamine-exposed children scored much higher in the Sleep Problems 
category, but this did not reach statistical significance (p=0.124). Again, while 
methamphetamine-exposed children averaged higher scores in most of the other 
categories (except Attention Problems, Internalising Problems and Affective 
Problems), this was not statistically significant.  
The cut-off for categorising clinical relevance for the categories of internalising-type 
behaviour, externalising–type behaviour and total behaviour problems is a t-score of 
≥63. A t-score of 60- 63 is borderline.  
The mean score for Internalising Behaviours in the children with methamphetamine 
exposure is 61.4 (SD 11.8), which falls into the borderline range, compared to a 
mean score of 59.2 (SD 11.9) for the control group which is not clinically relevant.  
The mean t-score for Externali ing Behaviours in the exposed group is 61.3 (SD 
13.2) which falls into the borderline range, compared to a mean score in the control 
group of 54.7 (SD 11.8) which again is not clinically relevant. The differences 
between scores on Internalising vs. Externalising Behaviours were not shown to be 



















The main purpose of this study was to identify and describe neurodevelopmental and 
behavioural disturbances of a cohort of methamphetamine-exposed children in the 
age bracket 2 to 4 years.  
There are many factors besides methamphetamine exposure during pregnancy 
which may influence performance of children in these areas.  
 
NEURODEVELOPMENT AND COGNITION 
Reviews have suggested certain developmental problems. Among those identified 
have been defects in visual system development, impaired spatial learning, sensory-
motor coordination and postural motor movements (36). 
 
A review published by Thompson et al linked methamphetamine and amphetamine 
exposure during fetal development with decreased arousal during the neonatal 
period and increased stress responses. Later in life these children exhibited 
movement disturbances and decreased scholastic achievement (36), with poorer 
performance on sustained-attention, long-term spatial and verbal memory, and visual 
motor-integration tests. The wide age range in this study (3-16 years) limits the 
ability to extrapolate specific age estimates, though.  
 
Cernerud and colleagues reported on longterm follow-up of alder children and 
adolescents exposed to MA antenatally. They identified an increase in language 
delays (20), and poorer performance in physical fitness activities and mathematics 
(21). Similar areas of concern were identified when researchers followed a cohort of 
Swedish children exposed to amphetamine during pregnancy: exhibition of emotional 
characteristics of autism, speech difficulties and stranger wariness by age 1(22); 
lower IQ’s vs norms by age 4(37); more aggressive behaviour and problems with 












especially due to delays in mathematics and language) and physical fitness activities 
by age 14 (38). 
Very limited data is available on the neurodevelopmental profile of preschool children 
with antenatal methamphetamine exposure. The majority of literature published on 
methamphetamine-exposed children was based on neuroradiological findings in 
children over wide age ranges, with findings that included smaller striatal structures 
on Magnetic Resonance Imaging (MRI) and elevated total creatine levels on 
Magnetic Resonance Spectroscopy (MRS), possibly a reflection of mitochondrial or 
glial cell dysfunction (19). Few studies have focused on intellectual functioning (32-
20, 21, 22, 23, 37, 38) 
Prior to enrolment, none of the children in our study group had ever been referred to 
Developmental Paediatrics services, despite parental or caregiver’s concerns in 
most of the methamphetamine-exposed cases. Our test results clearly showed that 
all the methamphetamine-exposed children met criteria for further developmental 
follow-up. Although specific problem areas were identified in all of the exposed 
children, for which they could receive remedial support, none of them at the time of 
testing were receiving any such assistance and would likely have entered the 
mainstream schooling environment with significant academic challenges. The above 
are clear indications of the inadequacy of systems in place to identify and support 
high risk children such as these in a resource limited environment. 
In general, methamphetamine-exposed children obtained lower scores on final 
‘General Quotients’ and performed at an age-equivalent lower than that of controls. 
 
Our findings on neurocognitive testing show that statistically significant problems 
were identified in personal-social ability and hand-eye co-ordination. These are 
important areas performance in the school environment. Similar to findings of other 
studies (20), our research also showed diminished performance on language ability. 
Although this did not reach statistical significance, qualitative comments from 
individual assessments frequently mentioned poor speech quality and paucity of 
vocabulary in general. Methamphetamine-exposed children also performed worse 











pattern-recognition (the ‘Performance’ subscale). Although these scores did not
reach statistical significance, they are considered important skills for daily living. 
As the number of children in both the subject and control groups in this study is so 
small, only tentative conclusions can be drawn from our findings on their neuro-
cognitive profile. However, areas of concern have been identified and that most of 
these correlate with what is already shown in the available literature regarding 
general cognitive ability, motor skills and language development. 
Environmental risk factors are particularly prevalent in the general South African
society, but probably more so in the communities from which these children were 
drawn. There are high incidences of parental and individual poor health, lower level
of maternal education, possible concomitant maternal depression and other drug or
alcohol use, violence, social isolation and poverty. Emotional problems can be both
common causes and consequences of cognitive and language disorders (33, 34).
Poverty, gang and other violence also affect the psychological and cognitive
development of young children (35). Learning difficulties, developmental delays and
behavioural problems are less likely to be picked up and/or acted upon in these
communities. Add recurrent illness, poor nutrition and limited access to preventative
primary care and these children face the cumulative burden of particular social stress
and greater biological vulnerability. 
BEHAVIOUR 
Previous literature highlights certain behavioural profiles of concern in children 
exposed to methamphetamine in utero. These included especially emotional 
characteristics of autism and stranger wariness (22) and an increase in aggressive 
behaviour and problems associating with peers (20, 23). 
Although our findings did not reach statistical significance, we feel it is clinically 
relevant that the scores on the Aggressive Behaviour subscale approached 












A trend toward significance was also found between groups on the Attention 
Deficit/Hyperactivity Problems subscale (p=0.0775). Attention deficit/ hyperactivity 
has not previously been identified as significantly increased in methamphetamine-
exposed children. These two areas of behavioural problems would again impact 
significantly on a child’s ability to interact appropriately and meaningfully in the 































Methamphetamine use often coincides with the use of other recreational drugs and 
alcohol. Alcohol use during pregnancy was not considered an exclusion criterion for 
this study, and as history of alcohol use during pregnancy was more or less equally 
reported between the two groups, the impact therefore on the developmental profile 
of each group may be considered similar. There was only one other mother in the 
subject group with additional use of marijuana during pregnancy.  
 
The nature of drug abuse and the accompanying lifestyle of participants made this a 
very difficult population to study. In most cases the child’s father was not involved, 
and often the mother was incarcerated or her whereabouts unknown. Addresses 
were mostly transient and telephone numbers disconnected or incorrect. When the 
child was eventually found, he or she was likely to be in protected care or fostered by 
a family member (in all our cases children were placed with a grandmother soon 
after birth, with variable visitation by parents). Appointments were frequently not kept 
due to a lack of transport or money, scheduled court appearances or the fact that the 
parent was still actively using recreational drugs.  
Due to the small sample sizes in both the methamphetamine-exposed group (N = 
15) and the control group (N = 21), the analysis lacks power. Therefore, differences 
that exist between the two groups may be less apparent.  
CBL questionnaires were completed by (mostly) foster parents for the subjects and 
biological parents (mostly mothers) for the controls. This discrepancy may have lead 
to some variation in reporting due to different expectations in regards to acceptable 
or problem behaviours. 
Despite these limitations, it remains important to document and further investigate 
our findings. Little is known about the neurodevelopmental and behavioral effects of 
methamphetamine exposure in pregnancy, especially in a resource-poor setting 















Although our sample size was small in this pilot study, the results do support findings 
elsewhere in the literature. New trends identified in our research further support the 
notion that methamphetamine is associated with significant neurodevelopmental and 
behavioural problems, some of which are already identifiable in early childhood and 
prior to formal school entrance. It would be valuable to continue studying this 
population formally for specific developmental and neurocognitive difficulties. 
 
Public health drives should target education and prevention of methamphetamine 
abuse in young, pregnant women in known high risk areas. 
 
Paediatric services should anticipate problems and aim to target exposed children 
for more intensive follow-up as early as the neonatal period, with developmental 
assessment, follow-up and educational and social support as soon as problems are 
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INFORMATION LEAFLET AND CONSENT FORM FOR ANTENATAL 
METHAMPHETAMINE EXPOSURE STUDY (English) 
(to be completed by parents or legal guardians of minors under 18 years) 
 
 
Trial title: Maternal Methamphetamine use during pregnancy and subsequent 
longterm neurodevelopmental and psychological sequelae in the child: a Cape Town 
experience 
 
Principal investigator: Dr Jessie van Dyk 
                                    Paediatrician 
                                    School of Child and Adolescent Health 
                                    Red Cross Children’s Hospital 
                                    Contact number: 0823329586 




Your child has been invited to take part in a research project. We have compiled some 
information on exactly why we are doing this study, why we have asked your child to take 
part, and what will happen during the course of this project. Please take some time to read 
through the brochure we are providing and then ask the study staff or doctor if you have any 
questions or concerns. We will need you to provide consent and sign the attached consent 
form before we can go any further, so it is very important that you fully understand exactly 
what our project entails and what will be expected of you and your child. Your child’s 
participation is completely voluntary and you can withdraw at any stage even if you agree to 
take part today. We would ask that, if you are uncomfortable with any of the processes or 
have concerns at any stage during the study, that you contact myself (Dr van Dyk) or Dr 
Donald before simply withdrawing, as we do believe that participating could have 
advantages for your child and your family. 
 
This study has been approved by the Committee for Human Research at the University of 
Cape Town will be conducted according to the ethical guidelines and principles of the 
International Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
Medical Research Council (MRC) Ethical Guidelines for Research. 
 
Why are we doing this study? 
 
It is well known that using any drug, and even some medicines, in pregnancy can potentially 
harm the growing fetus (developing baby). In the case of methamphetamine, known as ‘tik’ 
locally, there is not much research done on children yet, only some on animals and adults 












and because we have some evidence of what it can do to the pregnant mother, the placenta 
and the growing fetus, we are concerned that there could be development and learning 
problems in children whose mothers have used ‘tik’ in their pregnancies. These problems 
may not be as obvious when the baby is very small, but could progress as he or she gets 
older, end especially once they are about to, or are already school-going.  
 
We would like to evaluate children where the moms have obviously been concerned enough 
about the welfare of their babies by telling doctors about their drug use at the time of 
delivering their babies. If we were able to show that using ‘tik’ during pregnancy could cause 
learning, behaviour or developmental problems in the child later in life, then we could be 
more vigilant, know to do more regular developmental follow-up on these children and so 
provide early educational support to help ensure that they can lead as productive, full, happy 
lives as possible and achieve their full potential. . In order for us to make any assessments 
from such a study, we need to also test a group of non-exposed children and compare their 
test results with those of the children who are known to have been exposed. 
 
What would taking part in our study involve? 
 
With your permission we would like your child to take part in a few developmental, behaviour 
and psychometric tests and screens. These tests will help us identify any developmental 
problems (for instance if your child has not reached a specific milestone that is expected for 
his or her age), learning difficulties (for instance a problem with language or other areas that 
would affect his or her schooling) and behaviour problems (for instance Attention Deficit 
Hyperactivity Disorder). We will also do a full physical exam to make sure there are no other 
medical problems, and will test hearing and vision. We would also like you to complete 
questionnaires about aspects of your child’s behaviour and development. These tests will 
take roughly a morning to complete, and will be done at the Red Cross Children’s Hospital 
by Dr Jessie van Dyk, a general paediatrician, with the assistance of Dr Kirsty Donald of the 
Department of Neurology. 
 
Your child’s participation is completely voluntary and deciding not to take part will not have 
any detrimental effect on further treatment received at our hospital.  
 
What will you benefit from taking part? 
 
Parents or caregivers will have full access to the results of the tests, and should any 
problems be found, we will try to the best of our capabilities to provide the appropriate care 
and advice, as well as assist with further arrangements for special educational support and 
special multidisciplinary referral (such as occupational therapy, physiotherapy and other 
medical specialities). 
 
Who will have access to the study information and your child’s records? 
 
All information obtained from you and collected through testing will be treated as extremely 
confidential. We understand the sensitive nature of the information disclosed to us and the 
amount of trust involved in sharing it with us. In the event that information is used for 
publication or the completion of a thesis, the identities of participants and their family 
members will remain anonymous. The only people who will have access to the full 












ensure that no discrimination is experienced by participants or their families for any 
information disclosed. 
As part of ensuring the scientific validity of our study, the research records may need to be 
reviewed by auditors or the Research Ethics Committee.  
 
Will you be paid to take part and are there any costs involved? 
 
You will not be paid to participate in the study, but transport costs will be paid for yourself 
and your child for visits required during the study. As the testing days can become quite long 
and tiring, we will also provide snacks for especially your child for that time.  
 
Is there anything else you should know? 
 
If you have any further questions, or concerns about the study at any stage during the period 
of the study, please don’t hesitate to contact Dr Jessie van Dyk on 0823329586 or 
0124607900. 
 
You can contact the Committee for Human Research at 021-4066338 (Health Sciences 
Faculty, Research Ethics Committee, Room E52-24 Groote Schuur Hospital, Old Main 
Building, Observatory, 7925) if you have any concerns or complaints that have not been 









































I, …………………………………………………… hereby give consent for my  
 
child ………………………………………………………….. to take part in the  
 
research project entitled: Maternal methamphetamine use during pregnancy  
 
and subsequent long term neurodevelopmental and psychological sequelae 
 
for the child: a Cape Town experience. 
 
I declare that: 
1. I have read the information leaflet and consent form, or had it read to me 
2. both are written in a language with which I am fluent and comfortable 
3. I have been given a chance to ask questions and have received adequate 
answers to these questions 
4. I understand that taking part in this study is completely voluntary and I have 
not been pressurised to do so. 
5. I am aware that I may choose to leave the study at any time and will not be 
penalised or prejudiced in any way if I choose to do so 
6. I will receive a copy of this signed document 
 
Signed at (place) ………………………………………………………. 
 
































































INFORMATION LEAFLET AND CONSENT FORM FOR ANTENATAL 
METHAMPHETAMINE EXPOSURE STUDY  (English) 
(to be completed by parents or legal guardians of minors under 18 years) 
Trial title: Maternal Methamphetamine use during pregnancy and subsequent 
longterm neurodevelopmental and psychological sequelae in the child: a Cape Town 
experience 
Principal investigator: Dr Jessie van Dyk 
 Paediatrician 
 School of Child and Adolescent Health 




Your child has been invited to take part in a research project. We have compiled some 
information on exactly why we are doing this study, why we have asked your child to take
part, and what will happen during the course of this project. Please take some time to read
through the brochure we are providing and then ask the study staff or doctor if you have any
questions or concerns. We will need you to provide consent and sign the attached consent
form before we can go any further, so it is very important that you fully understand exactly
what our project entails and what will be expected of you and your child. Your child’s
participation is completely voluntary and you can withdraw at any stage even if you agree to
take part today. We would ask that, if you are uncomfortable with any of the processes or
have concerns at any stage during the study, that you contact myself (Dr van Dyk) or Dr
Donald before simply withdrawing, as we do believe that participating could have 
advantages for your child and your family.
This study has been approved by the Committee for Human Research at the University of 
Cape Town will be conducted according to the ethical guidelines and principles of the 
International Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
Medical Research Council (MRC) Ethical Guidelines for Research. 
Why are we doing this study? 
It is well known that using any drug, and even some medicines, in pregnancy can potentially 
harm the growing fetus (developing baby). In the case of methamphetamine, known as ‘tik’ 
locally, there is not much research done on children yet, only some on animals and adults 
who are using the drugs themselves. We know that it is harmful to animals and adult users, 











and the growing fetus, we are concerned that there could be development and learning 
problems in children whose mothers have used ‘tik’ in their pregnancies. These problems 
may not be as obvious when the baby is very small, but could progress as he or she gets 
older, end especially once they are about to, or are already school-going.  
We would like to evaluate children where the moms have obviously been concerned enough 
about the welfare of their babies by telling doctors about their drug use at the time of 
delivering their babies. If we were able to show that using ‘tik’ during pregnancy could cause
learning, behaviour or developmental problems in the child later in life, then we could be 
more vigilant, know to do more regular developmental follow-up on these children and so 
provide early educational support to help ensure that they can lead as productive, full, happy 
lives as possible and achieve their full potential. In order for us to make any assessments 
from such a study, we need to also test a group of non-exposed children and compare their 
test results with those of the children who are known to have been exposed. 
What would taking part in our study involve? 
With your permission we would like your child to take part in a few developmental, behaviour
and psychometric tests and screens. These tests will help us identify any developmental
problems (for instance if your child has not reached a specific milestone that is expected for
his or her age), learning difficulties (for instance a problem with language or other areas that
would affect his or her schooling) and behaviour problems (for instance Attention Deficit
Hyperactivity Disorder). We will also do a full physical exam to make sure there are no other
medical problems, and will test hearing and vision. We would also like you to complete
questionnaires about aspects of your child’s behaviour and development. These tests will
take roughly a morning to complete, and will be done at the Red Cross Children’s Hospital
by Dr Jessie van Dyk, a general paediatrician, with the assistance of Dr Kirsty Donald of the
Department of Neurology.
Your child’s participation is completely voluntary and deciding not to take part will not 
have any detrimental effect on further treatment received at our hospital. 
What will you benefit from taking part?
Parents or caregivers will have full access to the results of the tests, and should any 
problems be found, we will try to the best of our capabilities to provide the appropriate care 
and advice, as well as assist with further arrangements for special educational support and 
special multidisciplinary referral (such as occupational therapy, physiotherapy and other 
medical specialities). 
Who will have access to the study information and your child’s records? 
All information obtained from you and collected through testing will be treated as extremely 
confidential. We understand the sensitive nature of any information disclosed to us and the 
amount of trust involved in sharing it with us. In the event that information is used for 
publication or the completion of a thesis, the identities of participants and their family 
members will remain anonymous. The only people who will have access to the full 











ensure that no discrimination is experienced by participants or their families for any 
information disclosed. 
As part of ensuring the scientific validity of our study, the research records may need to be 
reviewed by auditors or the Research Ethics Committee.  
Will you be paid to take part and are there any costs involved? 
You will not be paid to participate in the study, but transport costs will be paid for yourself 
and your child for visits required during the study. As the testing days can become quite long 
and tiring, we will also provide snacks for especially your child for that time.  
Is there anything else you should know? 
If you have any further questions, or concerns about the study at any stage during the period 
of the study, please don’t hesitate to contact Dr Jessie van Dyk on 0823329586 or
0124607900. 
You can contact the Committee for Human Research at 021-4066338 (Health Sciences
Faculty, Research Ethics Committee, Room E52-24 Groote Schuur Hospital, Old Main
Building, Observatory, 7925) if you have any concerns or complaints that have not been














I, …………………………………………………… hereby give consent for my  
 
child ………………………………………………………….. to take part in the  
 
research project entitled: Maternal methamphetamine use during pregnancy  
 
and subsequent longterm neurodevelopmental and psychological sequelae 
 
for the child: a Cape Town experience. 
 
I declare that: 
1. I have read the information leaflet and consent form, or had it read to me 
2. both are written in a language with which I am fluent and comfortable 
3. I have been given a chance to ask questions and have received adequate 
answers to these questions 
4. I understand that taking part in this study is completely voluntary and I have 
not been pressurised to do so. 
5. I am aware that I may choose to leave the study at any time and will not be 
penalised or prejudiced in any way if I choose to do so 
6. I will receive a copy of this signed document 
 
 
Signed at (place) ………………………………………………………. 
 


























Printed name  Signature  Date 
Father: 
Printed name  Signature  Date 
Legal guardian: 
















INLIGTINGSBROSJURE EN TOESTEMMINGSVORM VIR VOORGEBOOR-TELIKE 
METAMFETAMIEN BLOOTSTELLING STUDIE (AFRIKAANS) 
(vir voltooiing deur ouers of wettige voogde van minderjarige kinders onder 18 jaar) 
 
Titel van studie: Moederlike Metamfetamien gebruik tydens swangerskap en 
daaropvolgende langtermyn neuro-ontwikkelings en sielkundige gevolge vir die kind: ‘n 
Kaapstad ervaring 
 
Hoof navorser:  Dr Jessie van Dyk 
                          Kinderarts 
                          School of Child and Adolescent Health  
                          Rooikruis Kinderhospitaal  
                          Kontak telefoon nommer: 0823329586 
                          E-pos: jessie.vandyk@doctors.org.uk 
 
Beste Ouer of Voog 
 
U kind word hiermee vriendelik uitgenooi om deel te neem aan ‘n navorsings- projek. Ons 
het die volgende inligtings-brosjure saamgestel om aan u te verduidelik  waarom ons hierdie 
studie aangepak het, hoekom ons u kind gevra het om daaraan deel te neem en wat presies 
tydens die verloop hiervan sal gebeur. Neem asseblief ‘n oomblik om daardeur te lees en 
vra dan gerus vir die studie personeel of dokter indien u enige verdere vrae of 
bekommernisse het. Ons benodig dat u asseblief u toestemming gee en die aangehegte 
toestemmingsvorm teken voordat ons kan voortgaan met enige toetsing, en daarom is dit 
uiters belangrik dat u presies verstaan waaroor die studie gaan en wat van u en u kind 
verwag sal word. U kind se deelname is volkome vrywillig en u kan ten enige tyd u kind 
onttrek, selfs al stem u vandag in. Ons vra nietemin dat, indien u op enige stadium 
ongemaklik is met enige van die prosesse of enige kwelling het, dat u dit asseblief onder my 
aandag (Dr van Dyk), of die van Dr Donald bring voordat u summier onttrek, omdat ons tog 
glo dat deelname aan die studie sekere voordele vir u kind en familie kan inhou. 
Hierdie studie is goedgekeur deur die Kommitee vir Menslike Navorsing van die Universiteit 
van Kaapstad, en sal uitgevoer word volgens die etiese riglyne en beginsels van die 
Internasionale Helsinki Deklarasie, Suid-Afrikaanse Riglyne vir Goeie Kliniese Praktyke and 
Mediese Navorsingsraad Etiese Riglyne vir Navorsing. 
 
Waarom doen ons hierdie studie? 
 
Dit is welbekend dat die gebruik van enige middels, en selfs sommige medikasies, tydens 
swangerskap potensieel skadelik kan wees vir die groeiende fetus (ontwikkelende baba). In 











dusver op kinders, net ‘n beperkte hoeveelheid op diere en volwassenes wat self die middel 
gebruik. Ons weet dat dit skadelike gevolge inhou vir volwasse gebruikers en diere daaraan 
blootgestel, en omdat ons bewyse het van die potensiele gevare vir die swanger ma, 
plasenta en die groeiende fetus, is dit ons kommer dat daar moontlik ontwikkelings en 
leerprobleme mag wees by kinders wie se ma’s ‘tik’ gebruik het tydens hul swangerskappe. 
Hierdie probleme mag moontlik nie eers sigbaar wees wanneer die baba klein is nie, maar 
later soos hy of sy ontwikkel en gereed maak om skool toe te gaan na vore kom.  
Ons wil daarom graag kinders evalueer waar die mammas ten tye van hul geboorte besorgd 
genoeg was oor die welvaart van hul baba’s om aan die dokter te erken dat daar ‘tik’ gebruik 
tydens swangerskap was. Indien ons kan bewys dat daar wel sekere ontwikkelings, gedrag 
of leerpropleme teenwoordig is by kinders etlike jare na hul blootstelling aan ‘tik’ tydens 
swangerskap, kan dit dokters and gesondheidsorg personeel in staat stel om meer pro-aktief
en oplettend te wees by sulke kinders, meer gereelde neuro-ontwikkelings opvolg te reël en
so vroeë onderwys ondersteuning kan bied om te help verseker dat sulke kinders hul vol
potensiaal bereik en aktiewe, gelukkige lewens kan lei. Om enige afleidings te kan maak van
so ‘n studie, moet ons egter ook ‘n groep kinders toets wat definitief nie blootgestel is aan 
metamfetamien tydens swangerskap nie, en hulle toetsuitslae vergelyk met die groep waar
daar blootstelling bekend is. 
Wat sal deelname aan ons studie behels? 
Met u toestemming sal ons u kind uitnooi om deel te neem aan ‘n reeks ontwikkelings,
gedrag en psigometriese toetse. Hierdie toetse sal ons in staat stel om te identifiseer indien
enige ontwikkelingsprobleme teenwoordig is (indien u kind byvoorbeeld nie ‘n bepaalde
verwagte mylpaal behaal het nie), moontlike leerprobleme (byvoorbeeld ‘n problem met taal
en kommunikasie, of ander areas wat toekomstige skoolvordering kan beinvloed) of
gedragsprobleme (byvoorbeeld Hiperaktiwiteit en Aandagafleibaarheid). Ons sal ook ‘n
volledige fisiese ondersoek uitvoer om seker te maak daar is geen ander mediese toestande
teenwoordig nie, asook gehoor en visie toetse. Terwyl u kind saam met ons speel, sal ons u 
versoek om ook ‘n vraelys te voltooi, wat ook sal handel oor aspekte van u kind se gedrag 
en ontwikkeling. Al hierdie toetse sal waarskynlik min of meer ‘n oggend neem om te voltooi
en sal uitgevoer word by die Rooikruis Kinderhospitaal deur Dr Jessie van Dyk, ‘n algemene 
kinderarts, met die ondersteuning van Dr Kirsty Donald, van die Departement Neurologie. 
U kind se deelname aan ons studie is ten volle vrywillig en indien u besluit om nie deel te 
neem nie, sal dit geen effek hê op toekomstige behandeling ontvang by ons hospitaal nie. 
Watter voordele is daar aan deelname aan ons studie? 
Ouers en voogde sal volle toegang hê tot die resultate van die toetse uitgevoer, en indien 











toepaslike ondersteuning en advies te bied, asook help met spesiale onderwys 
ondersteuning and verdere multidissiplinêre verwysing (byvoorbeeld na arbeidsterapie, 
fisioterapie en ander mediese spesialiste). 
Wie sal toegang hê tot die studie inligting en u kind se rekords? 
Alle inligting ingesamel tydens die verloop van die studie, hetsy deur toetse of van die 
vraelyste deur u voltooi, sal as uiters vertroulik beskou en hanteer word. Ons verstaan die 
sensitiewe aard van inligting aan ons verskaf en die hoeveelheid vertroue wat betrokke is 
tydens die deel van sulke inligting. Indien die resultate van ons studie vir publikasie 
doeleindes gebruik sou word of vir die voltooiing vir ‘n tesis of dissertasie, sal alle 
deelnemers aan die studie se identiteite anoniem gehou word. Die enigste persone wat 
toegang sal hê tot all studie-inligting versamel, is Drs van Dyk en Donald. Ons sal ook ons 
beywer om te sorg dat geen diskriminasie deur u of u kind of familie ondervind word vir
inligting aan ons oorgedra nie. 
Om te verseker dat ons studie aan al die nodige vereistes voldoen, mag ons rekords
moontlik deur ouditeure van die Navorsingsetiek Kommitee nagegaan moet word.
Sal ek vergoed word of sal ek moet betaal om deel te neem?
U sal nie betaal word om deel te neem aan ons studie nie, maar ons sal u wel vergoed vir
vervoerkostes vir uself en kind, vir besoeke gedurende die verloop van die studie. Omdat die
toetsdae ook moontlik lank en uitputtend kan wees, sal ons ook ‘n ligte maaltyd vir veral u 
kind verskaf. 
Is daar enigiets meer wat ek behoort te weet?
Indien u enige verdure vrae het, of bekommernisse ten opsigte van die studie, op enige 
stadium tydens die verloop daarvan het, moet u asseblief nie huiwer om  Dr Jessie van Dyk 
te kontak by 0823329586 of 0124607900. 
U kan ook die Kommitee vir Menslike Navorsing skakel by 021-4066338 (Fakulteit 
Gesondheidswetenskappe, Navorsingsetiek Kommitee, Kamer E52-24 Groote Schuur 
Hospitaal, Old Main Building, Observatory, 7925) indien u enige bekommernisse of klagtes 














Ek, …………………………………………………………. gee hiermee  
 
toestemming dat my kind, …………………………………………. mag  
 
deelneem aan die navorsingstudie getiteld : Moederlike metamfetamien  
 
gebruik tydens swangerskap en die langtermyn neuro-ontwikkelings en 
 
 sielkundige nagevolge vir die kind: ‘n Kaapstad ervaring 
 
 
Ek verklaar dat: 
 
1. ek die inligtingsbrosjure en toestemmingsvorm gelees het, of dat dit aan my 
voorgelees is 
2. albei geskryf is in ‘n taal waarin ek vlot is en gemaklik  kommunikeer 
3. ek ‘n kans gegun is om vrae te vra en voldoende antwoorde op hierdie vrae ontvang 
het 
4. deelname aan hierdie studie ten volle vrywillig is en ek onder geen druk geplaas 
word om deel te neem nie 
5. ek bewus is dat ek op enige stadium tydens die studie my kind en myself daarvan 
mag onttrek, sonder dat verdere behandeling van my kind by hierdie hospitaal 
daardeur beinvloed sal word 
6. ek ‘n kopie van hierdie vorm sal ontvang vir my eie rekords 
 
 
Geteken te (plek) …………………………………………………… 
 






















Naam in drukletters  Handtekening  Datum 
Vader: 
Naam in drukletters Handtekening  Datum 
Wettige voog: 
Naam in drukletters  Handtekening  Datum 














INLIGTINGSBROSJURE EN TOESTEMMINGSVORM VIR VOORGEBOOR-TELIKE 
METAMFETAMIEN BLOOTSTELLING STUDIE (AFRIKAANS) 
(vir voltooiing deur ouers of wettige voogde van minderjarige kinders onder 18 jaar) 
 
Titel van studie: Moederlike Metamfetamien gebruik tydens swangerskap en 
daaropvolgende langtermyn neuro-ontwikkelings en sielkundige gevolge vir die kind: ‘n 
Kaapstad ervaring 
 
Hoof navorser:  Dr Jessie van Dyk 
                          Kinderarts 
                          School of Child and Adolescent Health  
                          Rooikruis Kinderhospitaal  
                          Kontak telefoon nommer: 0823329586 
                          E-pos: jessie.vandyk@doctors.org.uk 
 
Beste Ouer of Voog 
 
U kind word hiermee vriendelik uitgenooi om deel te neem aan ‘n navorsings- projek. Ons 
het die volgende inligtings-brosjure saamgestel om aan u te verduidelik  waarom ons hierdie 
studie aangepak het, hoekom ons u kind gevra het om daaraan deel te neem en wat presies 
tydens die verloop hiervan sal gebeur. Neem asseblief ‘n oomblik om daardeur te lees en 
vra dan gerus vir die studie personeel of dokter indien u enige verdere vrae of 
bekommernisse het. Ons benodig dat u asseblief u toestemming gee en die aangehegte 
toestemmingsvorm teken voordat ons kan voortgaan met enige toetsing, en daarom is dit 
uiters belangrik dat u presies verstaan waaroor die studie gaan en wat van u en u kind 
verwag sal word. U kind se deelname is volkome vrywillig en u kan ten enige tyd u kind 
onttrek, selfs al stem u vandag in. Ons vra nietemin dat, indien u op enige stadium 
ongemaklik is met enige van die prosesse of enige kwelling het, dat u dit asseblief onder my 
aandag (Dr van Dyk), of die van Dr Donald bring voordat u summier onttrek, omdat ons tog 
glo dat deelname aan die studie sekere voordele vir u kind en familie kan inhou. 
 
Hierdie studie is goedgekeur deur die Kommitee vir Menslike Navorsing van die Universiteit 
van Kaapstad, en sal uitgevoer word volgens die etiese riglyne en beginsels van die 
Internasionale Helsinki Deklarasie, Suid-Afrikaanse Riglyne vir Goeie Kliniese Praktyke and 
Mediese Navorsingsraad Etiese Riglyne vir Navorsing. 
 
Waarom doen ons hierdie studie? 
 
Dit is welbekend dat die gebruik van enige middels, en selfs sommige medikasies, tydens 
swangerskap potensieel skadelik kan wees vir die groeiende fetus (ontwikkelende baba). In 











dusver op kinders, net ‘n beperkte hoeveelheid op diere en volwassenes wat self die middel 
gebruik. Ons weet dat dit skadelike gevolge inhou vir volwasse gebruikers en diere daaraan 
blootgestel, en omdat ons bewyse het van die potensiele gevare vir die swanger ma, 
plasenta en die groeiende fetus, is dit ons kommer dat daar moontlik ontwikkelings en 
leerprobleme mag wees by kinders wie se ma’s ‘tik’ gebruik het tydens hul swangerskappe. 
Hierdie probleme mag moontlik nie eers sigbaar wees wanneer die baba klein is nie, maar 
later soos hy of sy ontwikkel en gereed maak om skool toe te gaan na vore kom.  
Ons wil daarom graag kinders evalueer waar die mammas ten tye van hul geboorte besorgd 
genoeg was oor die welvaart van hul baba’s om aan die dokter te erken dat daar ‘tik’ gebruik 
tydens swangerskap was. Indien ons kan bewys dat daar wel sekere ontwikkelings, gedrag 
of leerpropleme teenwoordig is by kinders etlike jare na hul blootstelling aan ‘tik’ tydens 
swangerskap, kan dit dokters and gesondheidsorg personeel in staat stel om meer pro-aktief
en oplettend te wees by sulke kinders, meer gereelde neuro-ontwikkelings opvolg te reël en
so vroeë onderwys ondersteuning kan bied om te help verseker dat sulke kinders hul vol
potensiaal bereik en aktiewe, gelukkige lewens kan lei. Om enige afleidings te kan maak van
so ‘n studie, moet ons egter ook ‘n groep kinders toets wat definitief nie blootgestel is aan 
metamfetamien tydens swangerskap nie, en hulle toetsuitslae vergelyk met die groep waar
daar blootstelling bekend is. 
Wat sal deelname aan ons studie behels? 
Met u toestemming sal ons u kind uitnooi om deel te neem aan ‘n reeks ontwikkelings,
gedrag en psigometriese toetse. Hierdie toetse sal ons in staat stel om te identifiseer indien
enige ontwikkelingsprobleme teenwoordig is (indien u kind byvoorbeeld nie ‘n bepaalde
verwagte mylpaal behaal het nie), moontlike leerprobleme (byvoorbeeld ‘n problem met taal
en kommunikasie, of ander areas wat toekomstige skoolvordering kan beinvloed) of
gedragsprobleme (byvoorbeeld Hiperaktiwiteit en Aandagafleibaarheid). Ons sal ook ‘n
volledige fisiese ondersoek uitvoer om seker te maak daar is geen ander mediese toestande
teenwoordig nie, asook gehoor en visie toetse. Terwyl u kind saam met ons speel, sal ons u 
versoek om ook ‘n vraelys te voltooi, wat ook sal handel oor aspekte van u kind se gedrag 
en ontwikkeling. Al hierdie toetse sal waarskynlik min of meer ‘n oggend neem om te voltooi
en sal uitgevoer word by die Rooikruis Kinderhospitaal deur Dr Jessie van Dyk, ‘n algemene 
kinderarts, met die ondersteuning van Dr Kirsty Donald, van die Departement Neurologie. 
U kind se deelname aan ons studie is ten volle vrywillig en indien u besluit om nie deel te 
neem nie, sal dit geen effek hê op toekomstige behandeling ontvang by ons hospitaal nie. 
Watter voordele is daar aan deelname aan ons studie? 
Ouers en voogde sal volle toegang hê tot die resultate van die toetse uitgevoer, en indien 











toepaslike ondersteuning en advies te bied, asook help met spesiale onderwys 
ondersteuning and verdere multidissiplinêre verwysing (byvoorbeeld na arbeidsterapie, 
fisioterapie en ander mediese spesialiste). 
Wie sal toegang hê tot die studie inligting en u kind se rekords? 
Alle inligting ingesamel tydens die verloop van die studie, hetsy deur toetse of van die 
vraelyste deur u voltooi, sal as uiters vertroulik beskou en hanteer word. Ons verstaan die 
sensitiewe aard van inligting aan ons verskaf en die hoeveelheid vertroue wat betrokke is 
tydens die deel van sulke inligting. Indien die resultate van ons studie vir publikasie 
doeleindes gebruik sou word of vir die voltooiing vir ‘n tesis of dissertasie, sal alle 
deelnemers aan die studie se identiteite anoniem gehou word. Die enigste persone wat 
toegang sal hê tot all studie-inligting versamel, is Drs van Dyk en Donald. Ons sal ook ons 
beywer om te sorg dat geen diskriminasie deur u of u kind of familie ondervind word vir
inligting aan ons oorgedra nie. 
Om te verseker dat ons studie aan al die nodige vereistes voldoen, mag ons rekords
moontlik deur ouditeure van die Navorsingsetiek Kommitee nagegaan moet word.
Sal ek vergoed word of sal ek moet betaal om deel te neem?
U sal nie betaal word om deel te neem aan ons studie nie, maar ons sal u wel vergoed vir
vervoerkostes vir uself en kind, vir besoeke gedurende die verloop van die studie. Omdat die
toetsdae ook moontlik lank en uitputtend kan wees, sal ons ook ‘n ligte maaltyd vir veral u 
kind verskaf. 
Is daar enigiets meer wat ek behoort te weet?
Indien u enige verdure vrae het, of bekommernisse ten opsigte van die studie, op enige 
stadium tydens die verloop daarvan het, moet u asseblief nie huiwer om  Dr Jessie van Dyk 
te kontak by 0823329586 of 0124607900. 
U kan ook die Kommitee vir Menslike Navorsing skakel by 021-4066338 (Fakulteit 
Gesondheidswetenskappe, Navorsingsetiek Kommitee, Kamer E52-24 Groote Schuur 
Hospitaal, Old Main Building, Observatory, 7925) indien u enige bekommernisse of klagtes 














Ek, …………………………………………………………. gee hiermee  
 
toestemming dat my kind, …………………………………………. mag  
 
deelneem aan die navorsingstudie getiteld : Moederlike metamfetamien  
 
gebruik tydens swangerskap en die langtermyn neuro-ontwikkelings en 
 
 sielkundige nagevolge vir die kind: ‘n Kaapstad ervaring 
 
 
Ek verklaar dat: 
 
1. ek die inligtingsbrosjure en toestemmingsvorm gelees het, of dat dit aan my 
voorgelees is 
2. albei geskryf is in ‘n taal waarin ek vlot is en gemaklik  kommunikeer 
3. ek ‘n kans gegun is om vrae te vra en voldoende antwoorde op hierdie vrae ontvang 
het 
4. deelname aan hierdie studie ten volle vrywillig is en ek onder geen druk geplaas 
word om deel te neem nie 
5. ek bewus is dat ek op enige stadium tydens die studie my kind en myself daarvan 
mag onttrek, sonder dat verdere behandeling van my kind by hierdie hospitaal 
daardeur beinvloed sal word 
6. ek ‘n kopie van hierdie vorm sal ontvang vir my eie rekords 
 
 
Geteken te (plek) …………………………………………………… 
 























Naam in drukletters  Handtekening  Datum 
Vader: 
Naam in drukletters Handtekening  Datum 
Wettige voog: 
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PARENTAL BACKGROUND QUESTIONNAIRE (English) 
Mother    Date: ____________________ 
Name 
Date of birth 
Occupation 





Own health status 
Father 
Name 
Date of birth 
Occupation 

















Legal guardian (if other than parents) 
Name  
Date of birth  
Occupation  
Highest level of schooling obtained  
Home language  
Marital status  
Monthly income  
Criminal offences  
Own health status  
 
































OUERLIKE AGTERGROND VRAELYS (Afrikaans) 
 





Hoogste graad op skool behaal  
Huistaal  
Huwelikstatus  
Maandelikse inkomste  
Kriminele oortredings  







Hoogste graad op skool behaal  
Huistaal  
Huwelikstatus  
Maandelikse inkomste  
Kriminele oortredings  



















Hoogste graad op skool behaal  
Huistaal  
Huwelikstatus  
Maandelikse inkomste  
Kriminele oortredings  
Eie gesondheidstatus  
 

































DESCRIPTION OF NEURODEVELOPMENTAL SCREENS  USED IN THIS STUDY: 
 
1. Griffiths Mental Development Scales. The scale to be used has been proven 
appropriate for an age group of 3-7years, and is a sophisticated assessment tool to 
evaluate the different aspects of normal infant and child development. It has been 
validated for use in children of different language groups in South Africa. The GMDS 
measures areas, or sub-scales of development according to the following categories: 
locomotor, personal-social, hearing and language, eye-hand co-ordination, fine 
motor performance and reasoning. Raw scores are calculated for each sub-scale by 
adding the total number of items passed on a particular sub-scale. Raw scores from 
all the sub-scales are then added to obtain a total raw score that can be converted 
and evaluated as either age equivalents, sub-quotients and general quotients, or 




4. Achenbach Parent Questionnaire. The Child Behaviour Checklist (Achenbach, 
2001) is completed by parents or guardians and is designed to assess behavioural 
problems and social competencies in children. There are two versions of the 
checklist: one for ages 18 months to 5 years and a second for ages 6 to 18 years. It 
consists of 113 questions each scored by way of three possible responses: 0= not 
true, 1= somewhat true and 2= very true, and is able to generate an 8 syndrome 
report, as well as three more general scores: a total score, internalising behaviour 
score (fearful, shy, anxious and inhibited) and externalising behaviour score 
(aggressive, anti-social and under-controlled). The questionnaire rates behaviour 



















APPENDIX  H:  Academic Pediatrics author guidelines 
http://www.elsevier.com/wps/find/journaldescription.cws_home/717484/authorinstructions    
Academic Pediatrics 
Official Journal of the Academic Pediatric Association  
Guide for Authors  
Overview  
Academic Pediatrics strives to improve the health and wellbeing of children, their families, and their 
communities through:  
Providing a forum for the publication of general pediatric studies, commentaries and reviews that 
are of interest to learners and professionals who care for children and adolescents;  
Helping to advance the field of academic pediatrics;  
Strengthening the research and educational base of academic pediatrics; and  
Providing the evidence base for optimal child health care, pediatric education, and child health 
policy.  
The content areas of the Journal reflect the general interests of Academic Pediatric Association 
members and other health professionals who care for children. Areas of particular interest include 
child health services research, quality of clinical care, pediatric education, child health policy, and 
research methodology. Content areas for the Journal include such diverse topics as adolescent 
medicine, child maltreatment and protection, chronic illness, community pediatrics, developmental 
and behavioral pediatrics, emergency medicine, environmental medicine, financing, global 
pediatrics, health disparities, holistic medicine, hospital medicine, informatics, injury, medical 
education across the continuum, pediatric advocacy, prevention, pediatric primary care problems, 
and public health.  
 
Please address editorial questions to: 
Peter G. Szilagyi, MD, MPH, Editor-in-Chief 
Academic Pediatrics  
Department of Pediatrics 
University of Rochester School of Medicine and Dentistry 
Strong Memorial Hospital 
601 Elmwood Avenue 
Box 777 
Rochester, NY 14642 
Phone: 585 275-5798 












e-mail: journal@academicpeds.org  
 
Article Types  
Research articles - Quantitative and Qualitative Research  
Most research articles published in the Journal use quantitative methods, and the maximum length 
for these manuscripts is 3500 words. The word limit for manuscripts reporting qualitative research is 
4000 words. Mixed methods research will also be accepted. Manuscripts reporting original research 
should have clear organization with:  
A structured abstract less than 250 words (see below);  
A brief description, no more than 40 words, of key findings for the What's New section  
An introduction that describes the importance of the problem addressed  
A methods section that briefly explains the study design and procedures. For randomized clinical 
trials (RCTs), please include the CONSORT flow diagram in the methods section, and submit the 
CONSORT Checklist with the manuscript. Academic Pediatrics will take into consideration the 
registration of RCTs in a public trials registry, as described by the International Committee of Medical 
Journal Editors (ICMJE).1  
A results section that describes the key characteristics of the sample and then describes the findings 
for the dependent (outcome) variables and key independent variables.  
A discussion section that begins with a brief statement of the important findings of the study and 
then places these results in the context of previous related research. Please make specific 
recommendations rather than a general plea for more research.  
Articles describing educational research and interventions should measure and report outcomes 
beyond participants' reactions and change in knowledge. Demonstration of the impact of 
educational interventions should include changes in observed behaviors of learners as a result of the 
intervention. Ultimately, new learned behaviors should have measurable impact through improved 
patient outcomes and/or enhanced child health. 
 
Brief Reports  
The Journal also publishes brief reports that describe interesting new ideas or innovations in 
pediatric medicine, health services, and medical education. Brief reports typically raise new 
questions of interest to the Journal readership. Brief reports should have no more than 2,000 words 
(excluding abstract, tables, and references) and a maximum of three tables or figures and 25 















Perspectives presents important pediatric topics, with an emphasis on research findings in the 
previous five years and identifying areas for future study. The Perspectives Editors solicit most 
articles with input about topics and potential authors from the Journal's senior editorial group. 
Authors will generally be respected authorities in the area and may include a fellow or junior faculty 
member as a co-author. The manuscript should be about 4500-5000 words. It should include an 
overview of key questions and important research in a field, indicating the recent advances in the 
underlying science, and ending with a vision of the research and/or policy issues that should be 
addressed in the near future. Where appropriate, Perspectives should also discuss implications for 
pediatric education and practice. The editors will work with authors as needed and may request an 
annotated outline of the manuscript. All Perspectives manuscripts are peer-reviewed. For questions 
or suggestions about a Perspectives topic, please contact Elena Fuentes-Afflick at 
efuentes@sfghpeds.ucsf.edu or John Pascoe at john.pascoe@wright.edu. 
 
Systematic Reviews  
Systematic, critical assessments of literature and data sources pertaining to one of four areas: 1) 
pediatric research methods, 2) pediatric education and pediatric professional development, 3) 
pediatric health policy, and 4) pediatric health care delivery. All articles or data sources should be 
selected systematically for inclusion in the review and critically evaluated, and the selection process 
should be described in the article. Typical length: 2000 to 3500 words (not including tables, figures, 
and references). Evidence tables that list specific studies would generally be published in an online-
only appendix, while the print version would include the critical summary tables. Any manuscript 
over 4000 words will not be considered unless this has been previously discussed with the editor.  
 
Submissions should meet at a minimum the standards published by an international group led by 
David Moher, Ph.D. of the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa 
entitled Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Authors 
should access the PRISMA Statement (www.prisma-statement.org), which consists of the 27-item 
PRISMA Checklist, the PRISMA Flow Diagram, and the PRISMA Explanation and Elaboration 
Document.2 The PRISMA Explanation and Elaboration Document also includes additional 
considerations for systematic reviews of non-randomized intervention studies or for other types of 
systematic reviews. We would encourage authors also to consider the recommendations of the 
Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group.3  
 
The submitted report should include all 27 PRISMA items listed on the PRISMA Checklist including 
the PRISMA Flow Diagram (Item 17 on the checklist). The flow diagram depicts the flow of 
information through the different phases of a systematic review. It maps out the number of records 
identified, included and excluded, and the reasons for exclusions. We will publish the flow diagram 












evidence tables to address Item 18 on the checklist in the online version only, which, nevertheless, is 
the article of record for the journal. 
 
The submitted manuscript should include a Title Page. On a separate page, list MeSH Key Words for 
the purpose of indexing the report. Include on a separate page an Abstract. Structure the abstract as 
a summary of the report and include the following headings, as applicable, as prescribed in the 
PRISMA checklist: Background; Objectives; Data Sources; Study Eligibility Criteria, Participants, and 
Interventions; Study Appraisal and Synthesis Methods; Results; Limitations; Conclusions and 
Implications of Key Findings; and Systematic Review Registration Number. For the body of the paper, 
use the major headings of Introduction, Methods, Results, and Discussion. Also, on a separate page, 
list Acknowledgments. Acknowledgments should specify the sources of funding for the systematic 
review and other support and note the role of the funders for the systematic review. Refer to the 
PRISMA Flow Diagram as a figure in the Results section. Include each figure and table as separate 
pages in the manuscript to follow the References. Use this journal's Instructions for Authors for 
details regarding citations. Along with the figures and tables, include on a separate page a box 
containing no more than 40 words to be entitled, "What this Systematic Review Adds" describing 
perhaps in three bullet points this systematic review's contribution to the literature. Also, include on 
a separate page a box containing no more than 40 words to be entitled "How to Use this Systematic 
Review" and discuss, perhaps in 3 bullets, how academic pediatricians should apply these findings to 
their work.  
 
In the Moment - Personal Narratives  
We invite submissions to "In the Moment", the personal narratives section of Academic Pediatrics. 
"In the Moment" is a forum for author  to relate their personal experience of pediatrics. We are 
seeking narrative pieces about research, contact with patients, the influence of mentors, the impact 
of policy and current events, and the relationship of the author's work to their lives and the lives of 
others. Essays should describe these experiences and make connections to larger themes in 
pediatrics education, research, policy, and clinical care. The section is a vibrant forum for all of us to 
relate the stories and perspectives that are such an important part of our work and ongoing medical 
education. 
 
Submissions should be no more than 2500 words in length and do not need abstracts or "What's 
New" descriptions. Data and the work of others must be appropriately referenced. Papers should be 

















The editors occasionally solicit brief (about 1000 word) commentaries regarding papers published in 
the Journal or recent reports of activities of interest to readers. Commentaries differ from 
Perspectives by being briefer and more focused on specific topics, questions, or manuscripts. If you 
wish to submit a commentary, please contact the editor-in-chief.  
 
Supplements  
The Journal publishes supplements on topics of interest to its readers. Authors interested in 
supplements to the Journal should contact the Editor-in-Chief to discuss interest and procedures. 
Supplements should have a guest editor, who helps with the initial review of manuscripts and 
organization of the supplement, as well as suggesting reviewers for the manuscripts. All manuscripts 
proposed for a supplement have external review (as with other submissions to the Journal), and final 
decisions on publication remain with the Journal's editors, in consultation with the guest editor for 
the supplement.  
 
Preparing a Manuscript  
Formatting  
All manuscripts should be prepared with standard word processing software. Text should be double 
spaced in 12 point font, and pages numbered. Tables should be placed together at the end of the 
manuscript. Black and white figures will be printed without charge. Authors bear the costs for 
printing colored tables or figures. Do not mail original artwork or printed forms. Figures should be 
saved separately as ppt, tif, eps, or jpg files. The online submission system is unable to process multi-
worksheet or multi-slide files. To submit such documents, save each worksheet table or slide in a 
separate file. Symbols and special characters should not be created graphically; instead, use the 
character set provided in your word processor. Use a legend as part of the figure when symbols are 
used. Do not use any automated word-processing features, such as track changes or citation links. 
 
Submission Letter  
All manuscripts begin with a submission letter. This letter should be included with the online 
submission but the original copy signed by all authors should be sent to the editorial office at the 
above address. The authors should affirm that:  
 
They are responsible for the reported research.  
They have participated in the concept and design, analysis and interpretation of data, and drafting or 












They are disclosing any affiliation, financial agreement, or other involvement of any author with any 
company or other organization with a financial interest in the subject matter in the submitted 
manuscript. The Journal generally prints information on potential conflict of interest.  
The manuscript is being submitted only to Academic Pediatrics, that it will not be submitted 
elsewhere while under consideration, that it has not been published elsewhere, and, should it be 
published in Academic Pediatrics, that it will not be published elsewhere—either in similar form or 
verbatim—without permission of the editors. These restrictions do not apply to abstracts or to press 
reports of presentations at scientific meetings. 
If the submitted paper contains data that have been previously published, are in press or currently 
under review by another publication in any format, the authors are required to submit a reprint or a 
copy of the manuscript to the Editor-in-Chief with a clarification of the overlap and justification for 
consideration of the current submitted manuscript. This requirement includes manuscripts with the 
same or similar authors and using the same data source. Final decisions on the appropriateness of 
additional publication remain with the Editor-in-Chief.  
An institutional review board reviewed and approved the research.  
Title Page  
The title page is the first page of all manuscripts. It includes:  
The manuscript's title;  
Names, degrees, department, affiliation, city and state of all authors;  
Name, mailing address, email address, phone and fax number of the corresponding author;  
3-5 keywords;  
Running title or header of no more than 60 characters including spaces;  
Separate word counts for the abstract and the main text;  
Acknowledgement of research or project support with the relevant agency, grant or project number, 
and the principal investigator;  
Description of potential conflicts of interest and corporate sponsors.  
Abstracts  
The abstract is the second page of all manuscripts with the exception of "In the Moment - Personal 
Narratives" for which an abstract is not required. Abstracts should be prepared with a structured 
format with a maximum of 250 words. Four elements should be addressed: objective, methods, 














What's New  
What's New provides authors an opportunity to summarize in 40 words or less how this research 
contributes to the knowledge base of the field.  
 
Manuscript Text  
The manuscript's text varies with the type of article submitted. Please consult the "Article Types" 
section for guidelines, and direct specific questions to the Editorial Office or section editor. 
 
All manuscripts, including title page, tables, figures, and references, should be prepared according to 
"Uniform requirements for manuscripts submitted to biomedical journals."4 Grammar, punctuation, 
scientific writing style and abbreviations should follow the American Medical Association Manual of 
Style, 9th edition.5 Please use conventional system measurements followed in parentheses by 
equivalent Systeme International (SI) values.6,7 Any uncommon abbreviations should be listed at the 
beginning of the article. Confidence intervals usually provide more helpful information than P values. 
 
References  
All authors should have read all cited references. Please number references in the order they appear 
in the text. Unpublished references or meeting abstracts should not be included although articles 
accepted for publication or in press are permissible. Include the names of all authors for six and 
fewer; for references with more than six authors, provide the names of the first three and then et al. 
References should be double- spaced and generally not exceed 35. Spell out journal titles or use 
standard AMA abbreviations. References should follow AMA style.  
 
Submitting a Manuscript  
 
Authors should submit all manuscripts through the Journal's editorial website,  
http://ees.elsevier.com/academicpeds/. The manuscript submission process is broken into a series 
of screens that gather detailed information about the manuscript, including title, article type, author 
listings, abstract, keywords, topical classifications, and that allow authors to upload all pertinent files 
including the submission letter, manuscript, figures, and tables. A detailed tutorial with a step-by-
step walk-through is available for download on the EES homepage 
 













• For each author 
 
o First name, middle name/initial, last name, credentials 
o Department/Institution  
o E-mail address  
• Cover letter with all authors' names and signatures 
• Manuscript title (you may copy and paste this from your manuscript)  
• Abstract (you may copy and paste this from your manuscript)  
• Key words  
• Manuscript in common word processing format. Do not submit the manuscript in PDF format. The 
manuscript file must include  
o Title page  
o Abstract (not required for In the Moment - Personal Narratives)  
o "What's New" description (also not required for In the Moment) and  
o Manuscript text with references.  
• Tables, figures or images in PDF, XLS, or PPT format or embedded at end of the manuscript file.  
 
One author must be specified as the correspondent with the Journal. He or she will receive all 
communications from the Editor. Provide full mailing address, phone and fax numbers, and e-mail 
address for the corresponding author on the title page. The Journal limits authors to a maximum of 
eight. Exceptions to this rule will require justification and approval by the Editor-in-Chief. 
 
After submitting the manuscript files, authors select the order in which the files will appear in a 
merged PDF file that the system creates. When the system finishes generating the PDF file, authors 
are directed to a page that allows review of the pdf-formatted manuscript. If the conversion is not 
correct, authors can replace or delete manuscript files as necessary. The final screen includes an 
"Ethics in Publishing" statement that authors should read and accept if in agreement. After 
reviewing the converted files, authors need to click on "Approve Submission." This completes the 
manuscript submission process.  
 













Three outside peer reviewers review most manuscripts. The Journal makes every effort to expedite 
this process. The average time from submission to initial decision is 39 days. As part of the 
submission process, you will be able to suggest possible peer reviewers. Suggested individuals 
should have no conflicts of interest, and should not have any knowledge of the submitted 
manuscript. Please indicate names of reviewers who may have a conflict of interest.  
 
Manuscript Status 
You can check the status of your manuscript at any time by: 
1. Logging into the system with your password  
2. Clicking on the link "Submissions Being Processed. 
 
This procedure will display the status of your manuscript during the submission/peer-review 
process. 
 
Acceptance Criteria  
 
Relevance to readers (esp., educators, scientists, policymakers, and clinicians) is of major importance 
in manuscript selection. Reports of original research will be judged on the importance and originality 
of the research; the scientific strength; the relevance to clinical care, programs, education, or policy; 
the clarity with which it is presented, and the novelty of the new knowledge it adds.  
 
The Journal will generally accept manuscripts in the following categories: reports of original 
research, particularly clinical, health services, and health policy research; systematic reviews of 
primary care and general pediatric topics; studies and descriptions of educational interventions; 
educational symposia; and papers regarding methodology. In general, commentaries and topic 
reviews will be limited to careful systematic reviews of the literature or to research agenda setting 
papers indicating important next steps in a field. The Journal does not publish clinical case reports  
 
Education interventions must include an evaluation component, preferably one that goes beyond 
increasing knowledge to assessing and demonstrating whether the intervention changes learners' 
behavior, skills, or potentially health care quality or outcomes. Multi-site education innovations are 













Journal Editorial Policies  
 
Conflict of Interest  
Conflicts of interest can arise for authors, reviewers and editors. Conflicts of interest can arise for 
authors, reviewers and editors. The Journal makes every effort to avoid such conflicts within its 
control by blinding editors for whom conflicts may exist and by selecting reviewers without obvious 
conflicts. We rely on authors to make similar efforts and to reveal potential conflicts of interest in 
areas of financial relationships, sources of research support, and writing or other assistance. For 
more information about conflicts of interest, please refer to the International Committee of Medical 
Journal Editors' Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing 
and Editing for Biomedical Publication at  http://www.icmje.org/#conflicts. Please direct specific 
questions regarding potential conflicts of interest to the Journal office at: 
journal@academicpeds.org. 
 
Academic Pediatrics requires that authors completely disclose all relevant financial or personal 
arrangements or interests at the time of submission of a manuscript. Disclosures should appear on 
the acknowledgement section of the manuscript, and should describe specifically all sources of 
funding for the study as well as the nature of the financial arrangements. If the manuscript is 
accepted for publication, the disclosure will be published. 
 
Authors should indicate the role of the study sponsor in terms of study design, fieldwork, writing of 
the manuscript, and decision to submit for publication. 
 
Authors should also specifically indicate in the acknowledgements if no conflicts of interest exist. 
 
Authorship Criteria  
In order to meet authorship criteria, each author must have participated sufficiently in the work of 
the study and manuscript to acknowledge publicly responsibility for the manuscript. At least one 
author must be able to take public responsibility for the entire work, from idea to complete 
manuscript. Academic Pediatrics follows published uniform recommendations for criteria for 
authorship (see references). All three of the following criteria must be met for authorship: 
 
 
1. Substantial involvement and contribution to the idea or the study question, or to the study design, 












2. Writing drafts of the manuscript, or reviewing drafts or revisions critically with substantial input; 
and  
3. Approval of the final version of the manuscript.  
Group Authorship  
The Journal limits authors to a maximum of eight. Exceptions to this rule will require justification and 
approval by the Editor-in-Chief. One person should be designated as the lead author. If authorship is 
attributed to a group of individuals, each individual must achieve the criteria for authorship 
described above. 
 
Duplicate Publication or Previous Publication  
Manuscripts submitted to Academic Pediatrics should not have been published previously and 
should not be under consideration by any other journal. If portions of the manuscript have been 
published or have been submitted to another journal, or if the submitted manuscript uses the same 
dataset as one that was used for another submission or publication, authors must provide copies of 
the published or submitted manuscript to the editors of Academic Pediatrics. Detection of duplicate 
publication may result in action by the editors according to international guidelines (see reference 
#2). 
 
Human Subjects  
Appropriate approval by all institutional or other human subjects review boards must be designated 
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We ran searches using the OVID search platform in the following databases: 
MEDLINE, EMBASE, PsycINFO, and CCTR.  We retrieved a total of 617 
references from all 4 databases.  All references were saved in an EndNote 
library used to identify the 116 duplicates.  The author reviewed the 
remaining 501 unique references against our inclusion criteria. 
 




The search strategy for MEDLINE (1948 to June 21, 2011) retrieved 120 
references of which 111 were unique and not duplicated in our other 
searches.  The following combination of MeSH and free text terms for  
 
Set History Results Comments 
1 methamphetamine/ or benzphetamine/ 6186 Methamphetamine 
Terms 
2 exp "congenital, hereditary, and 
neonatal diseases and abnormalities"/ 
or Prenatal Exposure Delayed Effects/ 
or exp "Embryonic and Fetal 
Development"/ or exp Embryonic 
Structures/ or exp Teratogens/ or exp 
PREGNANCY/ 
1683411 Pregnancy Filter 
terms 
3 exp mental disorders/ or exp "behavior 
and behavior mechanisms"/ or exp 
"psychological phenomena and 
processes"/ or exp neurologic 
manifestations/ or exp human 
development/ or exp fetal alcohol 
syndrome/ or exp Nervous System/ or 





4 exp central nervous system/ or exp 
central nervous system diseases/ or 
child development/ or exp Delirium, 
Dementia, Amnestic, Cognitive 
Disorders/ or exp psychophysiology/ or 
exp diagnostic techniques, 
neurological/ or exp 
neuropsychological tests/ or cerebral 
arteries/ or cerebrovascular 
circulation/ or brain chemistry/ or 
exp nerve growth factors/ or exp 
nervous system physiology/ or nervous 
system diseases/ or exp cranial nerve 
diseases/ or exp nervous system 
malformations/ or exp 
neurodegenerative diseases/ or exp 
neurotoxicity syndromes/ or exp 
nervous system/ or exp 
neurotransmitters/ or exp receptors, 














neurotransmitter/ or microcephaly/ or 
circadian rhythm/ 
5 exp mental disorders/ or mental 
health/ or exp personality/ or exp 
personality tests/ or psychological 
tests/ or exp social behavior 
disorders/ or exp behavior/ or exp 
adaptation, psychological/ or exp 
emotions/ or mental competency/ or 
attention/ or child psychiatry/ or 
child development/ or adolescent 
development/ or exp psychophysiology/ 
or exp neuropsychological tests/ or 
hallucinations/ or illusions/ or fetal 
alcohol syndrome/ or exp psychology/ 





BEHAVIOR, SOCIAL  
Filter terms 
6 communication/ or language/ or exp 
verbal behavior/ or exp nonverbal 
communication/ or exp communication 
disorders/ or language tests/ or exp 
psycholinguistics/ or exp language 
development/ or autistic disorder/ 
172353 COMMUNICATION AND 
LANGUAGE Filter 
terms 
7 intelligence/ or exp learning 
disorders/ or exp mental processes/ or 
exp aptitude tests/ or developmental 
disabilities/ or exp mental 
retardation/ or exp memory disorders/ 
or cognition disorders/ or exp child 
development/ or autistic disorder/ or 
fetal alcohol syndrome/ or cerebral 
palsy/ 
820654 INTELLIGENCE AND 
LEARNING Filter 
terms 
8 exp psychomotor performance/ or exp 
psychomotor disorders/ or exp movement 
disorders/ or exp gait disorders, 
neurologic/ or motor skills disorders/ 
or exp orientation/ or exp perception/ 
or exp movement/ or exp sensation 
disorders/ or exp nervous system 
physiology/ or exp perceptual 
disorders/ or exp ocular motility 
disorders/ or exp sensation/ or exp 
vision tests/ or cerebral palsy/ 
1349021 PSYCHOMOTOR AND 
SENSORY Filter 
terms 
9 Or/3-8 5619235 ALL 
NEURODEVELOPMENT 
Filter terms 
10 1 and 2 and 9 258 Base clinical set 




Disregard the short paragraph sections 
MEDLINE: 
 
The search strategy for MEDLINE (1948 to June 21, 2011) retrieved 120 
references of which 111 were unique and not duplicated in our other 













methamphetamine/ or benzphetamine/ AND Pregnancy terms AND Neurocognitive 
and developmental terms AND limited to human studies 
 
EMBASE  
The search strategy for EMBASE (1980 to 2011 Week 24) retrieved 417 
references of which 353 were unique and not duplicated in our other 
searches.  We used a combination of EMBASE and free text terms for  
 
 
Set History Results Comments 
1 methamphetamine/ or amphetamine 
derivative/ or benzphetamine 
14346 Methamphetamine 
Terms 
2 exp pregnancy/ or exp 
teratogenesis/ or exp teratogenic 
agent/ or prenatal development/ or 
prenatal drug exposure/ or exp 
prenatal exposure/ or exp 
embryonic structures/ or exp 
congenital disorder/ 
1223242 Pregnancy Filter 
terms 
3 exp mental disease/ or exp 
behavior/ or exp "psychological 
and psychiatric phenomena"/ or exp 
neurologic disease/ or exp human 
development/ or fetal alcohol 




4 exp central nervous system/ or exp 
central nervous system disease/ or 
child development/ or postnatal 
development/ or cognitive defect/ 
or "disorders of higher cerebral 
function"/ or exp 
psychophysiology/ or exp 
neurologic examination/ or 
neuropsychological test/ or brain 
artery/ or exp brain circulation/ 
or exp brain level/ or nerve 
growth factor/ or exp nervous 
system function/ or exp neurologic 
disease/ or exp cranial 
neuropathy/ or exp nervous system 
malformation/ or exp degenerative 
disease/ or exp "toxicity and 
intoxication"/ or exp nervous 
system/ or exp neurotransmitter/ 
or neurotransmitter receptor/ or 
microcephaly/ or circadian rhythm/ 
4193875 PHYSICAL BRAIN AND 
NERVOUS SYSTEM 
Filter terms 
5 exp mental disease/ or exp mental 
health/ or exp personality/ or exp 
psychologic test/ or exp 
sociopathy/ or exp behavior/ or 
exp mental capacity/ or exp 
attention/ or child psychiatry/ or 
postnatal development/ or child 
development/ or adolescent 
development/ or exp 
psychophysiology/ or 
neuropsychological test/ or exp 
hallucination/ or exp illusion/ or 
3022951 MENTAL HEALTH, 













fetal alcohol syndrome/ or exp 
psychology/ or defense mechanism/ 
6 interpersonal communication/ or 
communication skill/ or exp 
language ability/ or exp nonverbal 
communication/ or exp verbal 
communication/ or exp language/ or 
verbal behavior/ or exp 
communication disorder/ or 
language test/ or exp linguistics/ 
or language development/ or exp 
autism/ 
294952 COMMUNICATION AND 
LANGUAGE Filter 
terms 
7 exp intelligence/ or exp learning 
disorder/ or exp mental function/ 
or cognition/ or conation/ or 
personality/ or psychophysiology/ 
or aptitude test/ or developmental 
disorder/ or exp mental 
deficiency/ or exp memory 
disorder/ or cognitive defect/ or 
postnatal development/ or child 
development/ or adolescent 
development/ or exp autism/ or 
fetal alcohol syndrome/ or 
cerebral palsy/ 
1879637 INTELLIGENCE AND 
LEARNING Filter 
terms 
8 exp psychomotor performance/ or 
exp psychomotor disorder/ or exp 
motor dysfunction/ or exp 
psychomotor disorder/ or exp 
orientation/ or exp perception/ or 
exp "movement (physiology)"/ or 
exp sensory dysfunction/ or exp 
nervous system function/ or exp 
perception disorder/ or exp eye 
movement/ or exp eye movement 
disorder/ or exp sensation/ or exp 
vision test/ or cerebral palsy/ 
1858865 PSYCHOMOTOR AND 
SENSORY Filter 
terms 
9 Or/3-8 6454100 ALL 
NEURODEVELOPMENT 
Filter terms 
10 1 and 2 and 9 417 Base clinical set 




The search strategy for EMBASE (1980 to 2011 Week 24) retrieved 417 
references of which 353 were unique and not duplicated in our other 
searches.  The following combination of EMBASE and free text terms for  
 




The search strategy for PsycINFO (1967 to June Week 3 2011) retrieved 89 
references of which 37 were unique and not duplicated in our other 
searches.  This database content emphasizes psychological and developmental 
outcomes.  Given the small retrieval, the search was limited to the drug 














Set History Results Comments 




2 exp congenital disorders/ or 
prenatal exposure/ or prenatal 
developmental stages/ or embryo/ 
or fetus/ or teratogens/ or 
prenatal exposure/ or teratology/ 
or exp pregnancy/ or exp pregnancy 
outcomes/ 
31281 Pregnancy terms 
3 1 and 2 89 Base Clinical Set 




The search strategy for EMBASE (1980 to 2011 Week 24) retrieved 417 
references of which 353 were unique and not duplicated in our other 
searches.  We used a combination of EMBASE and free text terms for  
 
methamphetamine/ or benzphetamine/ AND pregnancy terms   
 
 
EBM Reviews - Cochrane Central Register of Controlled Trials  
 
The search strategy for CCTR (2nd Quarter 2011) retrieved 1 reference of 
which 0 were unique and not duplicated in our other searches.  The 
following combination of MeSH and EMBASE descriptor terms for  
 
Set History Results Comments 
1 methamphetamine/ or amphetamine 
derivative/ or benzphetamine 
153 Methamphetamine 
Terms 
2 exp "congenital, hereditary, and 
neonatal diseases and 
abnormalities"/ or Prenatal 
Exposure Delayed Effects/ or exp 
"Embryonic and Fetal Development"/ 
or exp Embryonic Structures/ or exp 
Teratogens/ or exp PREGNANCY/ or 
exp teratogenesis/ or exp 
teratogenic agent/ or prenatal 
development/ or prenatal drug 
exposure/ or exp prenatal exposure/ 
or exp congenital disorder/ 
22013 Pregnancy Filter 
terms 
3 exp mental disorders/ or exp 
"behavior and behavior mechanisms"/ 
or exp "psychological phenomena and 
processes"/ or exp neurologic 
manifestations/ or exp human 
development/ or exp fetal alcohol 
syndrome/ or exp Nervous System/ or 
exp Nervous System Diseases/  or 
exp mental disease/ or exp 
behavior/ or exp "psychological and 
psychiatric phenomena"/ or exp 





4 exp central nervous system/ or exp 
central nervous system diseases/ or 













child development/ or exp Delirium, 
Dementia, Amnestic, Cognitive 
Disorders/ or exp psychophysiology/ 
or exp diagnostic techniques, 
neurological/ or exp 
neuropsychological tests/ or 
cerebral arteries/ or 
cerebrovascular circulation/ or 
brain chemistry/ or exp nerve 
growth factors/ or exp nervous 
system physiology/ or nervous 
system diseases/ or exp cranial 
nerve diseases/ or exp nervous 
system malformations/ or exp 
neurodegenerative diseases/ or exp 
neurotoxicity syndromes/ or exp 
nervous system/ or exp 
neurotransmitters/ or exp 
receptors, neurotransmitter/ or 
microcephaly/ or circadian rhythm/ 
or exp central nervous system 
disease/ or postnatal development/ 
or cognitive defect/ or "disorders 
of higher cerebral function"/ or 
exp neurologic examination/ or 
neuropsychological test/ or brain 
artery/ or exp brain circulation/ 
or exp brain level/ or nerve growth 
factor/ or exp nervous system 
function/ or exp neurologic 
disease/ or exp cranial neuropathy/ 
or exp nervous system malf rmation/ 
or exp degenerative disease/ or exp 
"toxicity and intoxica ion"/ or exp 
nervous system/ or exp 
neurotransmitter/ or 
neurotransmitter receptor/ or 
microcephaly/ or circadian rhythm/ 
SYSTEM Filter 
terms 
5 exp mental disorders/ or mental 
health/ or exp personality/ or exp 
personality tests/ or psychological 
tests/ or exp social behavior 
disorders/ or exp behavior/ or exp 
adaptation, psychological/ or exp 
emotions/ or mental competency/ or 
attention/ or child psychiatry/ or 
child development/ or adolescent 
development/ or exp 
psychophysiology/ or exp 
neuropsychological tests/ or 
hallucinations/ or illusions/ or 
fetal alcohol syndrome/ or exp 
psychology/ or exp motivation/ or 
exp defense mechanisms/ exp mental 
disease/ or exp mental health/ or 
exp personality/ or exp psychologic 
test/ or exp sociopathy/ or exp 
behavior/ or exp mental capacity/ 
82167 MENTAL HEALTH, 












or exp attention/ or child 
psychiatry/ or postnatal 
development/ or child development/ 
or adolescent development/ or exp 
psychophysiology/ or 
neuropsychological test/ or exp 
hallucination/ or exp illusion/ or 
fetal alcohol syndrome/ or exp 
psychology/ or defense mechanism/ 
6 communication/ or language/ or exp 
verbal behavior/ or exp nonverbal 
communication/ or exp communication 
disorders/ or language tests/ or exp 
psycholinguistics/ or exp language 
development/ or autistic disorder/ 
or interpersonal communication/ or 
communication skill/ or exp 
language ability/ or exp nonverbal 
communication/ or exp verbal 
communication/ or exp language/ or 
verbal behavior/ or exp 
communication disorder/ or language 
test/ or exp linguistics/ or 
language development/ or exp 
autism/ 
5111 COMMUNICATION AND 
LANGUAGE Filter 
terms 
7 exp learning disorders/ or exp 
mental processes/ or exp aptitude 
tests/ or developmental 
disabilities/ or exp mental 
retardation/ or exp memory 
disorders/ or cognition disorders/ 
or exp child development/ or 
autistic disorder/  or exp
intelligence/ or exp learning 
disorder/ or exp mental function/ 
or cognition/ or conation/ or 
personality/ or psychophysiology/ 
or aptitude test/ or developmental
disorder/ or exp mental deficiency/ 
or exp memory disorder/ or
cognitive defect/ or postnatal
development/ or child development/
or adolescent development/ or exp 
autism/ or fetal alcohol syndrome/
or cerebral palsy/
28782 INTELLIGENCE AND 
LEARNING Filter 
terms 
8 exp psychomotor disorders/ or exp 
movement disorders/ or exp gait 
disorders, neurologic/ or motor 
skills disorders/ or exp 
orientation/ or exp perception/ or 
exp movement/ or exp sensation 
disorders/ or exp nervous system 
physiology/ or exp perceptual 
disorders/ or exp ocular motility 
disorders/ or exp sensation/ or exp 
vision tests/ or exp psychomotor 
performance/ or exp psychomotor 
disorder/ or exp motor dysfunction/ 
or exp psychomotor disorder/ or exp 














orientation/ or exp perception/ or 
exp "movement (physiology)"/ or exp 
sensory dysfunction/ or exp nervous 
system function/ or exp perception 
disorder/ or exp eye movement/ or 
exp eye movement disorder/ or exp 
sensation/ or exp vision test/ or 
cerebral palsy/ 
9 Or/3-8 164794 ALL 
NEURODEVELOPMENT 
Filter terms 
10 1 and 2 and 9 1 Base clinical set 
and Final results 
 
EBM Reviews - Cochrane Central Register of Controlled Trials  
 
The search strategy for CCTR (2nd Quarter 2011) retrieved 1 references of 
which 0 were unique and not duplicated in our other searches.  This 
database consists exclusively of RCTs, no study design terms were used. The 
following combination of primarily MeSH and free text terms for  
 
methamphetamine/ or benzphetamine/ AND pregnancy terms AND Neurocognitive 
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